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  Atherosclerosis is a disease characterized by cholesterol-rich plaques 
within the intima of medium and large arteries. Cholesterol deposition is thought 
to occur by infiltration of low-density lipoprotein (LDL) into lesions followed by 
uptake into macrophages, generating lipid-loaded “foam cells.” Foam cells can 
also be generated in vitro by treatment of macrophages with LDL or oxidized 
LDL (oxLDL). The purpose of the current investigation was to determine the 
contribution of selective cholesteryl ester (CE) uptake versus whole-particle 
uptake during LDL-induced foam cell formation in cultured macrophages. 
Murine bone marrow-derived macrophages (BMMs) exhibited significant 
cholesterol accumulation when treated with LDL as indicated by quantification 
of cellular cholesterol and visualization of Oil Red-O-stained neutral lipid 
droplets. Uptake of LDL cholesterol was determined by measuring uptake of 3H 
and 125I into BMMs during treatment with [3H]CE/125I-LDL. [3H]CE uptake was 
linearly related to the LDL concentration at the concentrations used and was 
much larger than 125I uptake, indicating that the majority of LDL-cholesterol was 
acquired by nonsaturable, selective CE uptake. This pathway was demonstrated 
to be independent of whole-particle uptake by showing that inhibition of actin 
polymerization blocked LDL particle uptake but not selective CE uptake. 
Analysis by thin-layer chromatography (TLC) indicated that following uptake, 
[3H]CE was rapidly hydrolyzed into [3H]cholesterol by cells and largely effluxed 
into the culture medium. In contrast to LDL, studies of [3H]CE/125I-oxLDL 
uptake demonstrated that CE was acquired from oxLDL by whole-particle 
uptake with little or no selective CE uptake. Using a series of ten different 
[3H]CE/125I-oxLDLs oxidized for 0-24 hours, selective [3H]CE uptake was 
shown to be progressively impaired by LDL oxidation, while 125I-LDL particle 
uptake was increased as expected. Interestingly, the impairment of selective CE 
uptake occurred very early in LDL oxidation and this minimally oxidized LDL 
induced significantly less cholesterol accumulation in BMMs compared to native 
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LDL. Together, these results demonstrate that selective CE uptake is the primary 
mode of cholesterol uptake from LDL but not oxidized LDL, a finding that has 
important implications for cholesterol metabolism in atherosclerotic lesions. 
Future studies seek to identify the molecular components that participate in the 
macrophage selective CE uptake mechanism. 
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CHAPTER 1: INTRODUCTION 
The common perception of cardiovascular disease (CVD) as “clogging of 
the arteries with fat and cholesterol” reflects a widely accepted theory among 
scientists and health care professionals. This lipid hypothesis states that 
cholesterol is a major cause of CVD. The involvement of cholesterol in CVD 
has been a major focus of investigation for more than 100 years punctuated by 
many unexpected discoveries, including the identification of lipoproteins 
(reviewed in (1)), the low-density lipoprotein receptor (LDL-R) (2) that is 
deficient in many patients with familial heart disease and the finding of oxidized 
lipoproteins and their receptors (3). Some of these discoveries have been 
translated into life-saving therapies for patients with CVD.  For example, 
characterization of the regulation of LDL-R by cellular cholesterol led to the 
development of statins, HMG-CoA Reductase inhibitors that are the most 
commonly prescribed medicines in the world due to their unmatched ability to 
lower low-density lipoprotein (LDL) cholesterol and prevent fatal heart attacks. 
It is testament to the success of this area of research that the mortality from 
CVD in the United States has continuously decreased since 1960 and is less than 
half of what it was at that time, despite an aging population and increased 
prevalence of many other risk factors (4).  
Given the enormous scope of research on basic mechanisms of 
cardiovascular disease, it is surprising that there are no medications that directly 
target the primary lesion of these conditions, the atherosclerotic plaque. One of 
the most promising lines of research has been the study of macrophage-derived 
foam cells (5). These cells are present at every stage of the disease and appear to 
be critical regulators of pathogenesis. Specifically, the ability of these cells to 
scavenge LDL and other cholesterol-rich particles within atherosclerotic lesions 
 
 
2 
has been a major focus of investigation. The current paradigm is that LDL 
within lesions is first oxidized before it is taken up by macrophage scavenger 
receptors (6), converting these cells into cholesterol-loaded foam cells. However, 
this pathway has not been shown to be required in mouse models of 
atherosclerosis (7, 8), and accumulating evidence suggests that other mechanisms 
may be involved in the generation of macrophage foam cells (5). Further 
investigation is needed to investigate scavenger receptor-independent 
mechanisms of foam cell formation and their role in atherosclerosis. 
In the remainder of this review of literature, I provide a context for 
research in lipoprotein metabolism and macrophage foam cell formation, 
including clinical, pathological and biochemical considerations that contribute to 
the current understanding of how these entities contribute to disease. It is not 
possible in this space to describe all of the major findings of this enormous 
research field; this review seeks rather to highlight the studies and concepts that 
had the greatest impact on the development or interpretation of the current 
research project. Specifically, studies of the cellular pathways involved in the 
uptake of lipoprotein particles and their cholesterol form a critical background 
for understanding the rationale and significance of this dissertation project and 
therefore have been given special emphasis. 
In the subsequent chapters, I present the major findings of this research 
project, including evidence for a novel selective cholesteryl ester (CE) uptake 
pathway of macrophage foam cell formation. By comparison to oxidized LDL 
uptake and other previously proposed mechanisms of LDL uptake, I show that 
the selective CE uptake pathway is distinct and is uniquely specific to native 
LDL. I discuss the implications of these findings for foam cell function in 
atherosclerotic lesions. Finally, I describe how this completed study fits into a 
larger research plan that seeks to identify specific mechanisms involved in this 
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and other pathways of macrophage LDL metabolism that may be useful targets 
in the treatment of cardiovascular diseases. 
 
PART I: OVERVIEW OF ATHEROSCLEROSIS 
Pathology of  atherosclerosis 
The normal artery wall is composed of three layers or tunicae: intima, 
media and adventitia. Atherosclerotic plaques are located exclusively in the 
intima, the layer closest to the lumen of the vessel. The distinguishing features of 
the plaques are lipid deposits, composed almost exclusively of cholesterol, 
cholesteryl ester (CE) and phospholipid that occur in various forms depending 
on the stage of the disease (Fig. 1.1). Lesions in the coronary arteries that supply 
the heart, as well as the carotid arteries that supply the brain, have particular 
clinical significance as the major underlying mechanisms of heart disease and 
cerebrovascular disease, respectively. In the following subsections, a brief 
description of the normal intima and of each stage of atherosclerosis is given, 
including factors relevant to the progression of the disease.  
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Figure 1.1. Stages of atherosclerosis. Based on the classification system 
introduced by Stary and colleagues (9). Intima is shown without media and 
adventitia for clarity. 
 
Normal intima 
The intima extends from the endothelium to the internal elastic lamina, 
the latter representing the inner boundary of the media layer. The thickness of 
the intima varies widely depending on the size of the artery, the anatomic 
location and the age of the individual, and can be 2-300 µm (10). The intima is 
further stratified into the endothelial cell layer with its basement membrane, a 
subjacent proteoglycan layer and a deeper musculo-elastic layer. However, these 
sublayers are not always visible in very thin intimas. In general, the normal intima 
is rich in extracellular matrix with sparse or scattered smooth muscle cells and 
rare macrophages. There are no lipid deposits visible by light microscopy in the 
normal intima. 
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Interestingly, although the endothelium is sealed with intercellular tight 
junctions, all of the protein components of plasma are found in the intima of 
normal arteries (11, 12). Of special interest is the presence of lipoproteins, 
including LDL (13-15). The LDL concentration in the normal intima is directly 
proportional to the plasma concentration and is nearly twice the autologous 
plasma value (16). In contrast, the larger very-low density lipoprotein (VLDL) 
and chylomicrons are not present in the normal intima and therefore may be 
excluded. Ex vivo equilibration studies indicate that the endothelium serves to 
concentrate or retain LDL within the intima (17). This feature is unique to the 
arterial intima, as other tissues and tissue fluids contain much lower 
concentrations of LDL (18). 
 
Stage I: Initial lesion 
The initial lesion of atherosclerosis (pre-fatty streak, Stary stage I) is 
defined by the appearance of lipid deposits that are too small to be visible by 
gross inspection (19). As the earliest stage of the disease, these lesions are most 
common in infants or children but can also be observed in adults, especially 
those with little atherosclerosis. By light microscopy, the intima is thickened and 
is punctuated with rare, isolated macrophage-derived foam cells or small clusters 
of such cells, with little other obvious change (Fig. 1.1). 
However, the greater magnification afforded by electron microscopy 
reveals a distinct population of extracellular lipid particles that are not found in 
normal intima. In addition to monomeric and aggregated LDL, initial lesions 
contain extracellular lipid droplets, lipid vesicles and free cholesterol (FC) crystals 
(Fig. 1.2) (20-24). The lipid droplets (40-200 nm in diameter) contain a shell of 
phospholipid and free cholesterol and a core of CE. They are much smaller than 
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and are therefore easily distinguished from the cellular lipid droplets found in 
foam cells (300-6000 nm) (25).  The vesicles (also ~40-200 nm) have an aqueous 
core surrounded by uni- or multi-lamellar lipid bilayers of phospholipid and free 
cholesterol. The crystals are nearly pure FC and are less numerous and smaller at 
this stage than droplets and vesicles (26, 27). These lipid particles are present in 
atherosclerosis-prone sites prior to and during the accumulation of macrophage-
derived foam cells (21, 23). Therefore, they may play a major role in progression 
of the lesion to the next stage, the foam cell-rich fatty streak (Stary stage II, next 
section). 
 
        
Figure 1.2. Major lipid deposits of atherosclerotic lesions and their inter-
conversion. (1) Cholesterol uptake from LDL into lesion foam cells and cellular 
lipid droplets. (2) Remodeling of LDL into extracellular deposits. (3) Release or 
degeneration of foam cell components into the extracellular space. The deposits 
are depicted approximately to scale, except FC crystals, which have a very large 
size range (nm – mm range). 
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All three types of particles, and indeed, virtually all of the cholesterol in 
atherosclerotic lesions is likely derived from LDL (Fig. 1.2, arrows (1) and (2) 
(24). Perhaps the strongest evidence for this comes from studies with 
radiolabeled acetate and cholesterol tracers, which established more than 50 
years ago that plasma cholesterol, rather than endogenous cholesterol 
biosynthesis, is the precursor for 95% of lesion cholesterol (28) (29, 30). The 
pathogenesis of the extracellular lipid particles is not completely clear but is 
thought to involve retention of LDL within the intima. This is called “the 
response-to-retention hypothesis of early atherogenesis” (31, 32). According to 
this theory, increased residence time or impaired turnover of LDL allows more 
time for LDL modification and processing within the intima. In vitro remodeling 
by lipolysis, oxidation and other modifications converts LDL into particles that 
closely resemble the extracellular particles found in lesions (24, 33-35). Indeed, 
the extracellular lipid droplets share some features with both LDL and VLDL 
and contain apolipoprotein B (apoB, the apolipoprotein of LDL and VLDL), but 
have higher FC to CE ratios compared to plasma LDL and contain very little 
triglyceride (36) (37). 
Interestingly, the organization and composition of the extracellular lipid 
particles in lesions is accurately predicted from considerations of the mutual 
miscibility of FC, CE and phospholipid (27), suggesting that physical forces may 
influence their formation during lipoprotein remodeling. For example, hydrolysis 
of the CE in LDL or lipid droplets converts them into vesicles that have a much 
greater capacity for the FC that is generated (33). Excess cholesterol that cannot 
be maintained in droplets and vesicles precipitates as FC crystals (26, 27). 
There are several reasons why LDL may be retained within lesions. First, 
turbulent blood flow in areas prone to lesion development may contribute to 
impaired removal of lesion LDL (38, 39). The rate of diffusion of LDL out of 
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lesions is most likely controlled by the concentration gradient driven by the sheer 
of flowing blood (40). Diffused particles are quickly swept away in vessels with 
high sheer, maintaining a continuous concentration gradient that promotes the 
removal of LDL from lesions (41, 42). The fluid mechanics at these sites also 
induce specific cellular responses in endothelial cells and smooth muscle cells, 
including outward vessel remodeling, oxidative stress, inflammatory gene 
expression and enhanced transport of blood components into the artery wall (43, 
44), all of which may impact LDL transit and modification.  
Second, LDL binding to extracellular matrix may enhance LDL retention. 
A greater percentage of LDL in lesions compared to normal intima is tightly 
bound and can only be removed with detergent (e.g. triton X-100) (45). 
Extracellular matrix-bound LDL can be observed by electron microscopy in pre-
lesional segments of intima of hyperlipidemic animals and humans (31). LDL is 
known to interact specifically with proteoglycans, a major component of 
extracellular matrix that can bind massive amounts of LDL in vitro (especially 
versican or decoran which can bind 50-100X its weight in LDL)(46).  In contrast 
to LDL, albumin does not specifically interact with proteoglycans and is not 
retained in the intima (45). LDL-proteoglycan interactions are reversible (non-
covalent) (see above, from (46)) and the dissociation constants for proteoglycans 
common in the arterial intima (1-100 µM), indicate that the concentration of free 
LDL must be high (more than 500 µg/mL of LDL protein, assuming a 
molecular weight of ~500 kDa for apoB) in order to promote binding to 
proteoglycans. Interestingly, increased ex-vivo binding of plasma LDL to 
proteoglycans is associated with clinical markers of atherosclerosis in humans. 
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Stage II: Fatty streak 
Fatty streaks (Fig. 1.1, Stary stage II) are clearly differentiated from initial 
lesions and normal intima by distinct, large lipid deposits that are often grossly 
visible through the endothelium. These lesions are present in almost all 
individuals including children, and like the initial lesions have no pathological 
significance except that some may progress to more advanced lesions. At this 
stage, the lipid content of the lesion is localized almost entirely within engorged 
foam cells that are derived from macrophages, and to a lesser extent, smooth 
muscle cells (47). These foam cells are much more numerous than in precursor 
lesions and form sheets or large clusters. Indeed, foam cells make up most or all 
of the volume of fatty streaks. Extracellular lipid deposits are also found at this 
stage but are less abundant compared to intracellular lipid. 
Much effort has been expended in the study of mechanisms of foam cell 
generation, and this topic is a focus of the current dissertation project (see 
section 1.3. of this chapter). Macrophages are the major precursors of foam cells 
in most stages of atherosclerosis (except the fibroatheroma, discussed in a later 
section of this chapter)(47). These cells enter the lesion as blood monocytes via 
diapedesis and chemoattractant homing (5, 48). In the lesion, monocytes 
differentiate into macrophages and are regulated by a number of factors, 
including modified LDL (as mentioned in the previous section) and macrophage 
colony stimulating factor (M-CSF) (5). M-CSF promotes macrophage 
differentiation, proliferation and survival and is required for the development of 
atherosclerosis in genetic (49, 50) and diet-induced (51) hypercholesterolemic 
mice. In contrast, GM-CSF, another growth factor that promotes macrophage 
differentiation and survival, appears to be protective in the setting of 
atherosclerosis (52). 
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Once present within the lesion, macrophages accumulate large quantities 
of lipid within cytoplasmic lipid droplets. As stated above, it is generally accepted 
that foam cells derive their cholesterol from uptake of oxidized LDL. The role of 
LDL and modified LDLs in macrophage foam cell formation will be discussed 
in a subsequent section of this chapter. Macrophages may also impact the 
environment of the lesion in many ways, including inducing further monocyte 
recruitment, scavenging extracellular lipid and cellular debris and remodeling the 
extracellular matrix, to name a few examples (5). 
 
Stage III - IV: Preatheroma and atheroma 
The expansion of extracellular lipid deposits into large pools marks the 
progression to intermediate and advanced lesions (preatheroma and atheroma, 
Fig. 1.1) (19). These pools typically form and expand in the peripheral zone of 
the intima, immediately deep to the foam cell layer (Fig. 1.1). Analysis of lesions 
by light microscopy gives the impression that these lipid pools are not present at 
earlier stages of disease; however, it is now clear that they are composed mostly 
of the same extracellular vesicles, lipid droplets and FC crystals that characterize 
earlier lesions. The crystals become larger at this stage and may be visible by 
polarized light microscopy (26). 
When sufficiently large, lipid pools coalesce into a very large central pool 
that is often visible on gross inspection. This pool is referred to as the “lipid 
core” or “necrotic core,” the latter term referring to the presence of dead cells 
and cellular debris. The lipid core defines the advanced lesion (atheroma, Stary 
stage IV) and also gives atherosclerosis its name: “athero” is derived from the 
Greek “athere” or gruel that refers to the pasty texture of the lipid core. In the 
advanced plaque, cells are arranged in lamina between the endothelium and the 
lipid core, with the layers closer to the lipid core containing more lipid inclusions 
 
 
11 
(9). Interestingly, rather than intermingling, macrophage- and smooth muscle 
cell-derived foam cells form distinct layers, suggesting either mutual exclusion or 
local proliferation (53). 
Expansion of the extracellular lipid pools may be due to accelerated LDL 
retention and remodeling (Fig. 1.2, arrow (2)), or the release of stored cholesterol 
from damaged or dying foam cells (Fig. 1.2, arrow (3)). Analysis of the lesion 
lipid composition, which becomes progressively closer to the lipid composition 
of LDL, supports mainly the former hypothesis. The fatty acyl composition of 
CE in lesions is strikingly similar to plasma LDL (54-56).  The most common 
fatty acyl groups of both LDL and lesion CE, in order from the most abundant, 
are linoleate (18:2, n-6), oleate (18:1, n-9), palmitate (16:0), arachidonate (20:4, n-
6) and palmitoleate (16:1, n-9), which together make up more than 90% of all 
CE species. Fatty streaks differs the most from plasma LDL composition, with 
cholesteryl oleate more abundant at the expense of cholesteryl linoleate, and 
other species are similar to plasma LDL. Oleate is the preferred substrate for the 
acyl-CoA-acyltransferase (ACAT) enzyme expressed in foam cells, explaining the 
increased cholesteryl oleate in foam cell-rich fatty streaks. Advanced lesions have 
“CE fingerprints” nearly identical to serum LDL (56).   
 
Stage V: Fibroatheroma 
Advanced lesions may also develop a fibrous component (fibroatheroma, 
Fig. 1.1). In contrast to other plaques, fibroatheromas are characterized by a 
predominance of smooth muscle cells rather than macrophages, present in large 
numbers with many smooth muscle-derived foam cells (9). Fibrous tissue in 
lesions derives from smooth muscle cells that migrate through the lipid-rich zone 
to the endothelium and synthesize extracellular matrix. This results in the 
formation of a fibrous cap, an important protective barrier that stabilizes 
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plaques. Plaque stability is controlled by the balance of extracellular matrix 
synthesis and degradation, and is a critical determinant of the clinical outcome of 
the disease. 
 
Stage VI: Complicated Lesion 
Destabilization may result in erosion or rupture of the endothelial and 
fibrous layers, leading to communication between the lesion contents and the 
bloodstream with possible hemorrhage and/or thrombus formation 
(complicated lesions, Fig. 1.1) (9). These defects typically occur in areas where 
thinning of the fibrous cap allows close proximity of the lipid core to the 
endothelium, and can also occur in atheromas that do not have a fibrous 
component. Complicated lesions are responsible for the majority of morbidity 
and mortality associated with atherosclerosis. Ongoing research seeks to define 
the mechanisms of plaque remodeling, including the contribution of 
macrophage-derived foam cells to plaque destabilization, but these 
considerations are beyond the scope of the current investigation. 
 
Clinical context of  atherosclerosis 
Atherosclerotic cardiovascular disease (ACVD) is the most common 
cause of death in the world (57). The lesions do not themselves produce any 
symptoms and are not easily detected without invasive imaging procedures (58). 
However, this condition becomes clinically evident in two major contexts. First, 
when the expansion of the plaque encroaches upon the area of the vessel lumen 
sufficiently to significantly restrict blood flow (generally requiring 70% occlusion 
or stenosis), the result is insufficient oxygen delivery and tissue ischemia. This 
may present as angina (chest pain due to myocardial ischemia), claudication (calf 
pain due to lower limb ischemia), or a number of other pain syndromes 
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depending on the location. When arterial stenosis is severe and/or long-standing, 
infarction (tissue death due to hypoxia) or organ failure may result. Second, the 
plaque may rupture, leading to thrombosis and sudden occlusion of the vessel 
with infarction of downstream tissues. The latter mechanism is responsible for 
most cases of myocardial infarction (heart attack) and stroke, two major 
contributors to morbidity and mortality in cardiovascular disease (58). 
The current treatment of ACVD includes primary prevention of 
atherosclerosis together with treatment of the complications of tissue ischemia 
and infarction. Primary prevention is based on managing the major risk factors 
for ACVD by lifestyle modification (smoking cessation, weight loss, reduced fat 
and calorie intake and exercise) as well as medications to control plasma 
cholesterol, glucose and blood pressure. 
As mentioned in the introduction, there are currently no medications 
directed at reducing established atherosclerotic lesions directly. The only 
treatments for atherosclerosis per se are surgical and include endarterectomy 
(separation and removal of the plaque from the arterial wall), angioplasty 
(enlargement of a narrowed vessel by breaking and stretching the lumen) and 
bypass grafting (creation of a new arterial segment to bypass a diseased artery). 
However, these procedures carry a significant risk and are usually not curative as 
plaques continue to develop in the new or remodeled arteries. The development 
of new medications that induce or accelerate the regression of atherosclerotic 
lesions would be a major advance in the treatment of cardiovascular diseases. 
 
Summary of  atherosclerosis and discussion  
In the current model of atherosclerosis, retention of LDL in the arterial 
intima is the first step of pathogenesis. Retained LDL may then bind to 
proteoglycans and extracellular matrix, and/or become oxidized or remodeled 
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into extracellular lipid particles. Retained and modified lipoproteins induce the 
recruitment of circulating monocytes, which differentiate into macrophages and 
scavenge the LDL by a number of possible mechanisms, depending on the 
nature and degree of LDL modification. Excessive uptake of LDL cholesterol by 
macrophages and smooth muscle cells converts these cells into foam cells. 
Enhanced foam cell death and/or the inability of these cells to remove 
extracellular LDL cholesterol results in extracellular lipid expansion and necrotic 
core formation. Destabilization of the plaque followed by rupture and 
thrombosis result in the major clinical entities associated with the disease. 
Following many years of research, the composition of atherosclerotic 
lesions at each stage of disease is reasonably well described and understood 
(reviewed in previous sections of this chapter). Major unresolved questions 
include the relationship between LDL and the various types of lipid deposits 
found in lesions, and the pathways that may lead to their metabolism and 
interconversion (Fig. 1.2, arrows). This dissertation focuses on the uptake of 
cholesterol from LDL into macrophage foam cells (Fig. 1.2, arrow (1)). The 
remainder of this chapter will review specific mechanisms of cellular lipoprotein 
uptake that are relevant to foam cell formation. 
 
PART 2: BASIC MECHANISMS OF CELLULAR LIPOPROTEIN UPTAKE 
  
The LDL Receptor (LDL-R) 
The LDL-R was the first mechanism of cellular lipoprotein uptake to be 
identified (2). Early evidence for cellular lipoprotein uptake came from studies of 
the regulation of cholesterol biosynthesis. It was known that the presence of 
serum cholesterol (within lipoproteins) in the growth media of cultured cells 
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reduced the production of endogenous cholesterol by inhibiting the rate-limiting 
enzyme of cholesterol biosynthesis, HMG-CoA reductase. In a series of studies 
of cultured skin fibroblasts from patients with familial hypercholesterolemia 
(FH), Goldstein and Brown discovered both the genetic defect in these patients 
and part of the solution to the HMG-CoA reductase problem. The FC cells were 
missing a cell-surface LDL binding site (later identified as the LDL receptor, 
LDL-R), which normally serves to bind LDL and promote its internalization into 
the cell, delivering the cholesterol contained within the LDL. 
Goldstein and Brown used LDL that was radiolabeled in its protein (125I-
LDL) or CE ([3H]CE-LDL) components to delineate the pathway of LDL 
uptake that was missing in the FH fibroblasts (2). They found that LDL binds 
with high affinity to its receptor (Kd = 15 µg/mL LDL protein) (59). Following 
binding, the entire receptor-LDL complex is internalized in clathrin-coated pits 
to enter the cell via endocytic vesicles. The demonstration that LDL is taken up 
as whole particles rather than by extraction of the LDL cholesterol involved a 
comparison of the rates of LDL protein and CE uptake (using 125I-LDL and 
[3H]CE-LDL, respectively) and indicated an important difference between LDL-
R and the high density lipoprotein (HDL) receptor, as discussed below. LDL-
containing endosomes are then trafficked to late endosomes and lysosomes, 
where proteases and lysosomal acid lipase (LAL) degrade the LDL protein and 
CE, respectively. Released free cholesterol regulates cellular cholesterol 
homeostasis by inhibiting the HMG-CoA reaction, and is also used as a substrate 
for CE synthesis and storage, catalyzed by acetyl CoA-acyltransferase (ACAT). 
The degraded protein is released from cells and is detected in the culture media 
as 125I-amino acid. Importantly, like HMG-CoA reductase, LDL-R is under 
feedback control, and elevated cellular cholesterol that occurs with LDL 
treatment, for example, reduces LDL-R expression. Therefore, LDL uptake does 
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not lead to excessive cellular cholesterol accumulation in fibroblasts, as LDL-R is 
down-regulated during cholesterol loading. 
Of course, it is not fibroblasts but hepatocytes that express LDL-R 
relevant to plasma LDL metabolism, and this was confirmed by a number of 
investigators in collaboration with Goldstein and Brown (2). FH patients that are 
heterozygous or homozygous for the mutant LDL-R gene have plasma LDL 
half-lives of 4.5 and 6 days, compared to 2.5 days for a normal individual. This 
corresponds to a 3-fold higher catabolic rate of LDL in normal patients versus 
FH homozygotes, indicating that LDL-R contributes about two-thirds of normal 
LDL uptake in tissues. Liver transplantation into FH homozygous individuals 
corrects their hypercholesterolemia, indicating that the liver is the major site of 
LDL-R-mediated LDL uptake in humans. However, the ultimate demonstration 
of the importance of hepatic LDL-R in humans has come from the clinical 
success of the statins. These HMG-CoA-reductase inhibitors increase LDL-R 
expression by blocking endogenous cholesterol biosynthesis and thereby relieve 
the cholesterol-mediated repression of LDL-R expression. These agents can 
reduce plasma LDL cholesterol levels by more than 50% (60) due to increased 
hepatic LDL-R expression and accelerated LDL clearance. 
  
Acetylated LDL and SR-A 
It is clear that LDL-R is not the only pathway of cellular cholesterol 
accumulation, as FH patients without this receptor develop extensive deposits of 
cholesterol-loaded foam cells in their skin (xanthomas and xanthelasmas) and 
arteries (accelerated atherosclerosis). Even in normal individuals, excessive 
cholesterol accumulation in arterial foam cells does not suggest the involvement 
of LDL-R, since this receptor is under tight feedback control. Goldstein and 
Brown reasoned that macrophages utilize another pathway for LDL uptake 
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during foam cell generation. Indeed, initial studies of cultured murine peritoneal 
macrophages (MPMs) indicated that these cells do not express LDL-R and 
therefore do not exhibit high-affinity LDL binding and uptake (61). Instead, 
macrophage LDL uptake is characterized by low-affinity and non-saturable 
concentration dependence (see section below). 
However, it was soon discovered that chemical modification of LDL by 
acetic anhydride creates a ligand (acetylated LDL, acLDL) that is capable of 
inducing macrophage foam cell formation (61). During this treatment, acetic 
anhydride converts the lysine residues to acetyl-lysines, neutralizing the charge of 
the amino groups. Macrophage acLDL uptake is high-affinity and is much 
greater than macrophage LDL uptake at low LDL concentrations. Similar to the 
LDL-R pathway, acLDL binds to a macrophage cell-surface receptor (the 
“acLDL receptor”). This binding can be competitively inhibited by excess 
acetylated LDL, as well as by a wide variety of molecules with the shared 
property of being highly negative charged: maleylated lipoproteins and albumin, 
polyinosic acid and polyguanidinylate, dextran sulfate, fucoidin, carragheenan, 
and phosphatidylserine (62). The receptor was also called “scavenger receptor” 
due to its expression being limited to phagocytic or scavenging cells (63). acLDL 
binding initiates internalization of the whole acLDL particles (both protein and 
lipid components together) and lysosomal degradation by proteases and LAL, 
releasing FC into the cells. However, unlike LDL-R, the acLDL receptor is not 
under feedback control by cellular cholesterol, and uptake of acLDL continues 
despite extensive cholesterol deposition in the cells.  Therefore, macrophages 
treated with acLDL accumulate massive amounts of intracellular cholesterol, 
most of it converted into numerous cytosolic CE droplets by ACAT, giving the 
cells CE content and morphological appearance similar to foam cells in 
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atherosclerotic lesions. acLDL-treated macrophages was the first and remains 
the most popular experimental model of macrophage foam cells. 
The receptor for acetylated LDL was identified by Krieger and colleagues 
in 1990 by ligand affinity and immunoaffinity chromatographic purification from 
bovine lung, followed by partial amino acid sequencing and cDNA cloning (64, 
65). This resulted in the discovery of two protein products that are derived from 
alternative splicing of the same gene. These were named “scavenger receptor, 
types I and type II,” but after identification of a second class of scavenger 
receptors (discussed below), were renamed “scavenger receptor A, types I and 
II” (SR-A). When either of these proteins were transfected in chinese hamster 
ovary cells (CHO) lacking endogenous SR-A, high-affinity acLDL binding and 
acLDL-induced lipid droplet formation were bestowed (66), confirming that SR-
A is the acLDL receptor and showing that no other macrophage-specific protein 
is required for the cholesterol loading induced by acLDL. 
 
Oxidized LDL and CD36 
It is clear that acLDL is not found in animals and therefore this modified 
LDL is only an experimental model. The major biologically relevant ligand of the 
acLDL receptor is oxidized LDL (oxLDL). oxLDL uptake in macrophages is 
enhanced relative to native LDL, and oxLDL competes with acLDL for the 
same binding site (67). Several lines of evidence support a possible role for 
oxLDL in atherosclerosis. Unlike acLDL, oxLDL may be generated under 
potentially physiologic conditions such incubation with endothelial cells (67). 
Oxidized lipids and degraded apoB (both present in oxLDL) are found to be 
present in human atherosclerotic lesions (68). oxLDL itself can be isolated from 
lesions (68). Conversely, exogenous antioxidants prevent atherosclerosis in 
several animal models. In addition to promoting foam cell formation, oxLDL 
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possesses a number of other properties that may be relevant to atherogenesis: it 
activates endothelium and induces leukocyte adhesion molecules (69), it is toxic 
to cells including macrophages (70), and it is immunogenic as antibodies to 
oxLDL can be found in humans and experimental animals (71, 72). Together, 
these observations led to the widespread belief that oxLDL formation is a critical 
step in atherogenesis.  
The chemistry of LDL oxidation is much more complex than LDL 
acetylation and merits a brief description here. LDL oxidation proceeds by a 
defined series of molecular changes, in which polyunsaturated fatty acids 
(PUFAs) contained within LDL phospholipids and CE are key mediators (for a 
detailed review, see (73)). Initial oxidation of conjugated double bonds in 
PUFAs, which may occur enzymatically (e.g. by lipoxygenase) or 
nonenzymatically, leads to the formation of lipid hydroperoxides, which 
decompose to free radical-containing peroxyl- and alkoxyl-lipids. Lipid peroxide 
decomposition is catalyzed by transition metals such as Cu+ and Fe++. The 
generated free radicals are initially scavenged by the natural antioxidants of LDL, 
the caretenoids and tocopherols, resulting in a lag phase. However, after these 
are consumed, PUFA oxidation accelerates, consuming the PUFA in LDL and 
converting it en mass to hydroperoxides that decompose to hydroxides, ketones 
and other products. Some of the lipid products react with the protein of LDL, 
apoB, resulting in peptide bond scission and apoB fragmentation, as well as lipid 
adduction. Therefore, the composition of LDL is dramatically altered during 
oxidation, with all of the major components converted into oxidized and/or 
degraded products, and leading in turn to reduced particle stability and a 
tendency for particle aggregation and fusion (74). Lipid adducts to apoB are 
especially important as these are analogous to the acetyl-lysines formed by 
 
 
20 
acetylation of LDL, and are required for binding of oxLDL to the acLDL 
receptor (75, 76). 
In addition to the acLDL receptor, a second binding site for oxLDL was 
inferred from competition studies and termed the “oxLDL receptor.” Both of 
these binding sites were later identified and genetically cloned (62). Interestingly, 
both receptors were also found to bind to bacterial products and apoptotic cells; 
therefore, they were renamed “scavenger receptors” for their ability to scavenge 
both modified LDL and other pathogenic and inflammatory milieu. The acLDL 
receptor was renamed scavenger receptor A or SR-A, and the oxidized LDL 
receptor scavenger receptor B (SR-B). However, SR-B turned out to be the same 
protein as the previously identified leukocyte receptor CD36, and the name 
CD36 remained the more popular name for this receptor. A number of other 
related macrophage scavenger receptors were also identified; however, studies 
with cultured macrophages from mice deficient in SR-A and CD36 indicated that 
these two receptors were responsible for almost 90% of the uptake of the major 
forms of oxidized and modified LDL (77). Studies of atherosclerosis in these 
mice were quickly underway, but surprisingly, produced conflicting results: a 
marked reduction in atherosclerosis found in some laboratories in the scavenger 
receptor-deficient mice (78-80), but no effect was found in other laboratories (7, 
81-83). Differences in the genetic background were cited as one possible 
explanation for the divergent results, but it was also suggested that the results 
might indicate that scavenger receptor-mediated oxLDL uptake is not the major 
mechanism of foam cell formation (84). 
 
The HDL receptor (SR-BI) and selective CE uptake 
LDL-R specifically binds and mediates uptake of LDL but not HDL, 
indicating that HDL metabolism occurs independently of this receptor. 
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However, no human or animal genetic condition leading to impaired HDL 
clearance was known at the time that the LDL-R pathway was discovered. The 
use of dual-radiolabeled HDL ([3H]CEt/125I-LDL), borrowed from Goldstein 
and Brown’s studies with cultured fibroblasts, led to an important clue in 1983. 
When injected into rats, the CE component of HDL was cleared more rapidly 
than the protein component and accumulated selectively in several tissues, 
including liver, adrenals and gonads (85, 86). This phenomenon was termed 
“selective lipid uptake” or “selective CE uptake.” Selective CE uptake was also 
observed when dual-radiolabeled LDL was injected into rats, albeit to a lesser 
degree compared to HDL. 
Selective CE uptake was also observed in certain cultured cells including 
hepatocytes and adrenal cortical cells, consistent with the involvement of a cell 
surface receptor analogous to LDL-R (85, 87, 88). Key features of the selective 
lipid uptake pathway in these cells included 1) uptake from both HDL and LDL; 
2) transfer of many lipids including CE, free cholesterol, triglyceride, 
phospholipid and vitamins; 3) a requirement for apolipoproteins and cell surface 
proteins, suggesting a specific binding event; 4) involvement of a reversible 
plasma membrane CE compartment as a precursor for irreversible uptake; 5) no 
requirement for endocytosis and 6) CE hydrolysis by a neutral CEase. 
Interestingly, during cloning of the macrophage scavenger receptors, one 
protein related to CD36 called scavenger receptor B, type I (SR-BI) was found to 
mediate selective CE uptake from HDL (89). In the same study, SR-BI was 
found to be highly expressed in the tissues known to be sites of selective CE 
uptake (liver, adrenals and gonads). Subsequent studies demonstrated that SR-BI 
is the major HDL receptor in mice and is involved in hepatic HDL CE clearance 
as well as the delivery of cholesterol to adrenals and gonads for the production 
of steroid hormones (90, 91). Recently, human mutations in SR-BI were shown 
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to be associated with elevated HDL cholesterol (HDL-C) and reduced urine 
corticosteroids, suggesting that SR-BI is likely to be a relevant HDL receptor in 
humans (92, 93). 
SR-BI-mediated selective CE uptake is a two-step process requiring first, 
“productive” binding of lipoprotein to the extracellular domain of SR-BI and 
second, selective delivery of CE into the cell mediated by its extracellular domain 
(91, 94). Studies in vitro showed that SR-BI is able to mediate SLU without 
requiring additional proteins or specialized cell structures. On the basis of 
thermodynamic and kinetic data, SR-BI was proposed to form a lipophilic 
channel between the bound lipoprotein particle and the plasma membrane (95), 
consistent with the identification of essential hydrophobic residues of SR-BI (96) 
and with the ability of SR-BI to mediate SLU in the absence of cellular energy 
(97). Indeed, the bulk of SR-BI selective CE uptake is generally considered to 
occur at the plasma membrane with the transfer of HDL CE into a reversible 
membrane pool that remains available for efflux back to HDL prior to 
internalization into the cell (87, 98). SR-BI can also promote HDL particle 
internalization, and intracellular selective transfer may make a small contribution 
to total selective CE uptake in hepatocytes (99). Following its selective uptake, 
CE is hydrolyzed to unesterifed cholesterol by neutral cholesterol esterase(s), the 
identities of which remain uncertain, although hormone sensitive lipase is 
responsible for the bulk of CE hydrolysis in steroidogenic cells (100).  It is also 
unclear whether hydrolysis takes place at the plasma membrane or possibly 
following the transfer of CE into the cytoplasmic compartment by an undefined 
mechanism. 
SR-BI protects against the development of atherosclerosis in mice, 
consistent with its ability to promote “reverse cholesterol transport,” the removal 
of cholesterol from atherosclerotic lesions and other peripheral sites and delivery 
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to the liver for biliary secretion and elimination (101-104). Interestingly, 
apoE/SR-BI double-knockout mice have very rapidly accelerated atherosclerosis 
as well as plaque rupture and fatal myocardial infarction, the latter sequelae 
representing features that have not otherwise been observed in mice.  
 
Alternate pathways of  LDL uptake 
Since the characterization of acLDL uptake, many types of LDL 
modification in addition to oxidation have been shown to result in increased 
macrophage uptake and foam cell generation (5). There is evidence that some of 
these modified forms of LDL occur in vivo, but without models to specifically 
inhibit their uptake by macrophages there is no direct evidence that any of these 
are required for foam cell generation in atherosclerotic lesions. 
Another possibility is that native LDL could directly promote foam cell 
generation without prior modification. As stated above, macrophages do not 
avidly take up LDL because they do not express the high affinity LDL receptor 
(61). However, a low affinity pathway for LDL uptake was suggested from early 
studies. It was later shown that at high concentrations (~1 mg/mL LDL), native 
LDL induces significant cholesterol accumulation and foam cell generation 
(105). The low affinity uptake pathway was shown to be actin polymerization-
mediated pinocytosis, with LDL particles entering cells in the fluid phase via 
macropinosomes and micropinosomes (106-108). Inhibition of these pinocytic 
pathways inhibits LDL uptake and the resulting cholesterol accumulation, 
confirming that pinocytosis in required for foam cell formation from native 
LDL. Ongoing studies have characterized the cell signaling pathways that control 
the rate of pinocytosis in macrophages, providing for several potential 
therapeutic targets to block foam cell formation in vivo (108). 
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Macrophage selective CE uptake 
In addition to hepatocytes and steroidogenic cells, selective CE uptake is 
also observed in macrophages. Macrophages take up CE selectively from both 
HDL and LDL (109-111). This pathway was shown in some conditions to be 
regulated by cellular cholesterol content, fatty acids and the oxysterol-responsive 
element liver X receptor (LXR) (111, 112). Increased cellular cholesterol 
resulting from LDL or acLDL treatment or by treatment with an ACAT 
inhibitor resulted in diminished selective CE uptake, while reduced cellular 
cholesterol resulting from serum starvation, fatty acids or LXR activation 
enhanced selective uptake. Selective lipid uptake is enhanced in atherosclerotic 
lesions of mice, indicating that macrophage selective uptake may be important 
during foam cell formation in vivo (113). 
However, very little is known about the mechanism of macrophage 
selective CE uptake. Importantly, macrophage selective CE uptake is 
independent of SR-BI in primary murine macrophages (114, 115) and the human 
macrophage cell line THP-1 (116). Previous reports suggested that the low 
density lipoprotein receptor-related protein (LRP) may be involved (117, 118), 
but these studies relied on an anti-LRP antibody that has not been demonstrated 
to exhibit specific blocking activity against LRP. Proteoglycans have also been 
implicated (112). Plasma membrane caveolae were shown to be the initial site of 
CE transfer in SR-BI expressing CHO cells (119) and were also suggested in 
macrophages (120). Enrichment of caveolae with FC may decrease the capacity 
for CE in these structures, thereby decreasing the selective CE uptake. Following 
selective uptake from HDL in human macrophages, CE was hydrolyzed in a 
chloroquine-resistant manner, suggesting a neutral hydrolase (109); however, 
there are no reports of the metabolism of LDL-derived CE in macrophages.  
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Macrophage selective CE uptake may be functionally important in at least 
two contexts. First, this pathway may contribute to whole-body lipoprotein 
metabolism. Kupffer cells (the resident macrophages of the liver) rather than 
hepatocytes are the major sites of hepatic LDL CE uptake in rats, supporting 
this possibility (121). Studies of the role of M-CSF, a major growth factor and 
stimulant of macrophages, also provide supportive evidence. Injection of M-CSF 
results in 2-fold enhanced LDL clearance, lowering plasma cholesterol by more 
than 30% in both normal and hyperlipidemic rabbits (122, 123). Conversely, M-
CSF-deficient mice have increased plasma cholesterol levels with much of the 
cholesterol present in large VLDL particles (49, 50, 124). More research is 
needed on the contribution of macrophages to plasma LDL metabolism. 
Second, selective CE uptake may be a mechanism of LDL metabolism in 
atherosclerotic lesions, possibly contributing to foam cell formation. This second 
possibility led to the major research question of the current investigation: to 
investigate the contribution of selective CE uptake to macrophage foam cell 
generation. 
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CHAPTER 2: MATERIALS AND METHODS 
Animals 
  Mice were housed in the Veterans Affairs Medical Center (Lexington, 
KY) and all experiments were approved by the Institutional Animal Care and 
Use Committee (IACUC). Animals were maintained in a pathogen-free facility 
with a 12-hr light/dark cycle and free access to food and water. 
 
Radiolabeled chemicals 
  Iodide-125 radionuclide (“125I”), [1, 2, 3H(N)]cholesterol (“[3H]FC”) and 
[Cholesteryl-1,2-3H(N)]-hexadecyl ether (“[3H]CEt”) were obtained from Perkin 
Elmer. [Cholesteryl 1, 2, 6, 7 H(N)] oleate (“[3H]CE”) was purchased from 
American Radiolabeled Chemicals. [1, 2, 3H(N)]cholesteryl linoleate (“[3H]CL”) 
and [1, 2, 3H(N)]cholesteryl palmitate (“[3H]CP”) were synthesized from [3H]FC 
by reaction with linoleic acid anhydride or palmitic acid anhydride as described 
below. 
 
Synthesis of  [3H]CL and [3H]CP 
  [3H]CL and [3H]CP were not available commercially and were required 
for some experiments (see chapter 4). [3H]CE synthesis was carried out by an 
adaptation of an established method (125). The basic reaction mechanism 
involved esterification of [3H]FC by reaction with fatty acid anhydride (Fig. 2.1). 
The hydroxyl group of the [3H]FC is the nucleophile in reaction with the 
anhydride, with [3H]CE and the corresponding fatty acid as products. The 
[3H]FC (50-200 µCi) was transferred in toluene to a clean 12x75mm borosilicate 
glass tube and dried under a gentle argon stream. Linoleic anhydride or palmitic 
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anhydride was dissolved in toluene (100 µM) and 100 µL was added to the tube 
containing the dried [3H]FC. The tube was sealed under argon gas, vortexed 
thoroughly and left in the dark at room temperature overnight. The next day, a 
very small aliquot (~0.2 µL) was taken to assess the reaction progress by thin-
layer chromatography (see below), typically >90% at this time. The crude 
reaction mixture was extracted with Dole reagent (isopropanol/heptane/acetic 
acid 40:10:1) and the organic layer transferred to a clean tube. Dole extraction 
was repeated twice and the recovery monitored by counting each fraction for 3H 
by liquid scintillation counting. The final 3H recovery was >95% after lipid 
extraction. The [3H]CE was purified from the lipid extract by semi-preparative 
TLC (see below). The final [3H]CE product was >95% pure by TLC of 3H with 
total yield of 20-80%. 
                           
Figure 2.1. Synthesis of [3H]CE from [3H]FC and fatty acid anhydride. 
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Analysis of  [3H]CE and [3H]FC by thin-layer chromatography 
   Silica-coated PVC thin-layer chromatography plates were purchased 
from Macherey-Nagel and were used for all TLC procedures. For some 
procedures in which the separation of CEs with different fatty acyl components 
was necessary (chapter 4), the plate was dipped into a freshly made solution of 
0.1% AgNO3 in dH2O, allowed to dry and activated by heating the plate at 80 ˚C 
for 1 hr. Plates were cut into pieces 5 cm wide and 2-20 cm long, depending on 
the number of samples. A line was drawn across the piece 1 cm from the edge, 
and tick marks were drawn 1 cm apart to mark sample-spotting positions. 
  Samples were extracted into or dissolved in organic solution 
(hexane/isopropanol or chloroform or other). For all TLC procedures, a small 
measured aliquot of the sample (2-15 µL) was counted directly by 3H scintillation 
counting to determine the total 3H content. Aliquots were then spotted onto the 
cross by allowing the sample to draw into a small plastic pipette tip by capillary 
action and touching the tip to the plate, which was estimated to deliver ~0.2 µL 
solution based on 3H quantification. The spot was allowed to dry with a gentle 
argon stream before spotting again. 
  After all samples were spotted, the plate was developed in a glass tank 
with one of two solvent systems: toluene or hexane/diethyl ether/acetic acid 
(70:30:1). Development was monitored continuously, and was stopped when the 
solvent front was ~1cm from the top of the plate, which typically required 3-5 
min depending on the solvent system. Therefore, the distance of development 
was 3 cm. The plate was removed and allowed to dry briefly, then was stained 
either by exposure to iodine in a glass tank, or by dipping the plate in a fresh 
solution of 0.05% ferric chloride in dH2O/acetic acid/sulfuric acid (90:5:5), 
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allowing the plate to dry again and then heating the plate at 100 ˚C for 5 minutes 
(Fig. 2.2). Each lane was cut out with scissors and divided into the CE and FC 
spots and the spaces between spots, and each piece was transferred to a 
scintillation vial with 5 mL of scintillation fluid and 3H quantified by scintillation 
counting. The data was expressed as a percent of total 3H in the entire lane, and 
the percent was multiplied by the total 3H content to determine the content of 
3H present as [3H]CE, [3H]FC and other. The TLC procedural loss was less than 
20% in each experiment, but this did affect the results, which were based on the 
total 3H content of the original sample. 
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Figure 2.2. Thin-layer chromatography analysis of [3H]CE and [3H]FC. 
Samples were spotted on plain TLC plates (A) or AgNO3-embedded plates (B) 
and developed for 3 cm with toluene (shown) or hexane/diethyl ether/acetic 
acid (70:30:1). Spots were visualized by dipping the plate in a fresh solution of 
0.05% ferric chloride in dH2O/acetic acid/sulfuric acid (90:5:5), allowing the 
plate to dry again and then heating the plate at 100 ˚C for 5 minutes. Spots were 
cut out and counted for 3H by scintillation counting (C-D). Data are expressed 
as % 3H in the spot of the total 3H in the lane. 
  It was observed that CE or [3H]CE that was dried and exposed to air, e.g. 
in a borosilicate glass tube or on a TLC plate, showed evidence of CE oxidation 
in less than 24 hr, with loss of intact CE and appearance of more polar, slowly 
migrating species (Fig. 2.3). Therefore, precautions were taken to minimize or 
avoid dry conditions were possible (by storing in organic solution and by 
working quickly after spotting samples onto TLC plates), and samples were 
stored at -20 ˚C under argon, conditions under which CE and [3H]CE were 
found to be stable (as assessed by TLC purity) for at least 2 years. 
  
                            
Figure 2.3. Autooxidation of CP, CO and CL. CEs were spotted onto a TLC 
plate at 0 h (CP, CO and CL) or 16 h (CP*, CO* and CL*) before developing the 
plate. Spots were visualized with the FeCl3 solution and heating method as 
described. 
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Other chemical chemicals and assays 
  Cholesterol and cholesteryl esters were purchased from Sigma. Total 
cholesterol (TC) and free cholesterol (FC) E-kits were purchased from Wako. 
Cytochalasin D, latrunculin B, the ACAT inhibitor CI-976, chloroquine and 
diethylumbelliferyl phosphate (UBP) were purchased from Sigma. Protein 
content of samples was determined by the method of Lowry et al. (for 
lipoprotein protein content)(126) or using a bicinchoninic acid (BCA) Protein 
Assay Kit (Thermo Scientific, for cell protein content). 
 
Lipoprotein isolation, characterization, radiolabeling and modification 
  LDL (ρ = 1.019–1.063 g/mL) and HDL (ρ = 1.063–1.21 g/mL) were 
isolated from human plasma by density gradient ultracentrifugation (127). 
Human HDL was subfractionated to obtain HDL3 (ρ = 1.13–1.18 g/mL). LDL 
and HDL were dialyzed against normal saline (0.9% w/v) with 0.3 mM EDTA. 
Protein concentrations were determined as described. Lipoproteins were 
analyzed by SDS-PAGE and non-denaturing gradient gel electrophoresis. LDL 
was 125iodinated by the iodine monochloride method (128). To measure LDL CE 
uptake, [3H]CEt or [3H]CE were incorporated into 125I-LDL using the CETP 
method as previously described (129). Alternately, to measure LDL FC uptake, 
[3H]FC was incorporated into 125I-LDL as described (130). After labeling, 125I 
and 3H specific activities were determined as dpm/nmol CE (for [3H]CEt/125I-
LDL and [3H]CE/125I-LDL) or dpm/nmol FC (for [3H]FC/125I-LDL). Specific 
activity with respect to the CE or FC content of the radiolabeled LDL was used 
so that uptake of cholesterol from LDL could be compared to changes in the 
measured cholesterol content of cells. Specific activities were between 2,000-
10,000 and 500-1,000 dpm/nmol CE for 125I and 3H, respectively. LDL was 
aggregated by vortexing at maximum speed for 30 seconds resulting in a milky 
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suspension, or was acetylated by repeated addition of acetic anhydride to LDL as 
previously described (131). 
 
Mouse peritoneal macrophage (MPM) and bone marrow macrophage 
(BMM) isolation and culture 
  Wild-type or class B scavenger receptor-deficient mice were injected with 
1 mL of BioGel 5 days before collecting MPMs or BMMs to increase the 
number of macrophages and/or precursors obtains. BMMs were the major 
experimental macrophage cell model for experiments and were obtained by 
standard procedures (132). Briefly, tibias and femurs were removed from 
anesthetized mice that were previously injected with BioGel, and the mice were 
subsequently euthanized by cervical dislocation. In sterile conditions, the bones 
are dissected to removed muscle and connective tissue, and then flushed with 
PBS to collect the bone marrow. Marrow cells were dispersed in PBS by passing 
through a 16 gauge needle 20 times, then pelleted by low speed centrifugation 
and resuspended in medium A (RPMI 1640 plus 15% (v/v) L-cell conditioned 
medium (LCM), 10% (v/v) heat-inactivated fetal bovine serum (FBS), 50 IU/mL 
penicillin G and 50 µg/mL streptomycin). Cells were plated in 12-well plates 
(with or without glass cover slips for microscopy and cholesterol content 
determination, respectively) or in 48-well plates (for radiolabeled LDL uptake 
experiments) at a ratio of bone marrow of 1 mouse per plate. BMMs were 
cultured in medium A for 7 days before being used for experiments, and culture 
media was changed on days 3, 5, 6, and 7. 
  MPMs were collected by standard procedures by euthanizing 
anesthetized mice that had been previously injected with BioGel by cervical 
dislocation. The peritoneal cavity was flushed with 40 mL of sterile PBS, 
collected into a tube and peritoneal cells pelleted by low speed centrifugation. 
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The pellet was resuspended in medium A (RPMI 1640 plus 15% (v/v) L-cell 
conditioned medium (LCM), 10% (v/v) heat-inactivated fetal bovine serum 
(FBS), 50 IU/mL penicillin G and 50 µg/mL streptomycin) at a concentration of 
cells from one mouse/4mL and plating in 48-well plates at 250 µL/well. Cells 
were incubated at 37˚C for 3 hours, and then washed to remove non-adherent 
cells and fresh medium A added. MPMs were cultured for 2 days before using in 
experiments, with the media changed on days 1 and 2. 
  BMMs differentiation was characterized by flow cytometric 
quantification of Mac1 (CD11b) and F4/80 expression in comparison to MPMs 
(Fig. 2.4). Cells were analyzed for size and granularity (e.g. as produced by 
cellular vesicles and inclusions) by forward scatter and side scatter, respectively. 
Bone marrow cells (day 0) were characterized by two major populations of cells 
with 48.4% larger, more granular cells (as expected for leukocytes and their 
precursors) and the remainder smaller and less granular. Of the larger cell 
population, ~91.8% and ~30.6% were positive for Mac1 and F4/80, 
respectively. By day 3, many of the cells in the well were floating (percent?), 
71.2% of which were large cells and of these, 95.1% and 8.9% were positive for 
Mac1 and F4/80, respectively. The attached cells were much more granular than 
the floating cells as indicated a 3-fold higher average side scatter value. Of the 
attached cells 87.9% were large cells and of these, 81.8% and 89.0% were 
positive for Mac1 and F4/80, respectively. At days 5 and later, >95% of cells fit 
into a single cell size and granularity population and were >95% positive for 
both markers. In comparison, MPMs cultured for 2 days as described were 100% 
within a single population of large, granular cells with very high expression of 
both Mac1 and F4/80. 
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Figure 2.4. Analysis of BMM differentiation by flow cytometry. Size and 
granularity. Bone marrow cells (Day 0) or BMMs were collected on the 
indicated day and analyzed by flow cytometry for size (FSC-H) and granularity 
(SSC-H) 
 
 
35 
 
Figure 2.5. Analysis of BMM differentiation by flow cytometry. Mac1 and 
F4/80 expression. Bone marrow cells (Day 0) or BMMs were collected on the 
indicated day and analyzed by flow cytometry for Mac1 and F4/80 expression 
versus an isotype control antibody. 
 
 
36 
 
Microscopy and cellular lipid and protein content determinations 
  For microscopy, BMMs growing on glass cover slips were treated as 
indicated in Figure Legends, and then washed 1-3 times with PBS, fixed for 5 min 
in freshly prepared 1% paraformaldehyde and stained with Oil Red-O (ORO, 
fresh 3:2 dilution of 60% isopropanol stock solution). Cover slips were mounted 
onto glass slides with a drop of 70% glycerol, and images were obtained from at 
least 5 randomly chosen fields for each condition. For cellular lipid 
determination, lipid was extracted from cells with hexane/isopropoanol (3:2), 
dried and resuspended in aqueous solution with 1% Triton X-100/H2O. TC and 
FC content (nmol cholesterol/mg cell protein) were determined using 
Cholesterol E-kits as described in the instruction manual. CE content was 
calculated as the difference between TC and FC content. Cell protein was 
determined by BCA. 
 
Determination of  CE and FC uptake 
  LDL particle uptake and LDL CE selective uptake (discussed in detail in 
Chapter 1) are the main focus of this dissertation and were the most commonly 
measured experimental variables during the course of the project. These 
parameters were quantified by a standard method, as recently described for HDL 
CE selective uptake (115). This determination involves several assumptions that 
were previously validated. These key assumptions (given as numbered 
statements) are defined and discussed below. 
 
(1) Uptake of whole LDL particles (LDL uptake) can be measured as the 
sum of cell-associated 125I-LDL and degraded 125I-LDL (TCA-
soluble 125I in the culture media) in cells treated with 125I-LDL. 
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(2) During LDL uptake, all of the components of the LDL particles are 
also taken up, delivering stoichiometric quantities of CE (“LDL 
CE uptake equivalents”) and other constituents of LDL. 
(3) “Total CE uptake” can be measured by quantification of [3H]CEt 
accumulation in cells treated with [3H]CEt-LDL. 
(4) “Total CE uptake” can also be determined by quantification of the 
sum of cell-associated [3H]CE, cell-associated [3H]FC and released 
[3H]FC in cells treated with [3H]CE-LDL. 
(5) “Selective CE uptake” is defined as, and is calculated from, the 
difference between total CE uptake and the amount of CE uptake 
that is contributed by uptake of whole LDL particles.   
 
  Statement (1) is a key assumption in this dissertation but was validated 
many years ago (61, 133, 134). Statement (2) is important because the calculation 
of selective CE uptake requires that 125I-LDL uptake and [3H]CEt (or [3H]CE) 
uptake are expressed in the same units (discussed below). Statements (3) and (4): 
[3H]CE hydrolysis by cellular esterases generates [3H]FC that may be effluxed 
from cells. In some experiments, a tracer that cannot be hydrolyzed is desirable 
to simplify the uptake determination. [3H]CEt is a non-hydrolyzable analog of 
CE that is intracellularly trapped and commonly used to measure selective CE 
uptake (135). Statement (5) defines selective CE uptake as previously described 
(115). 
  The basic CE uptake experiment involved treating BMMs or other cells 
with radiolabeled LDL as indicated in Figure Legends in medium B (RPMI 1640 
plus 15% (v/v) LCM, 0.5% (w/v) fatty acid-free BSA (Sigma), 20 mM HEPES 
pH 7.4, 50 IU/mL penicillin G and 50 µg/mL streptomycin). After the 
treatment period, cells were lysed by the addition of 0.1 M NaOH, and lysates 
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collected and counted for cell-associated 125I-LDL. Cell lysates were also used to 
determine cell protein content (mg/well) by BCA. Culture medium was 
precipitated with trichloroacetic acid (TCA), chloroform extracted and the 
aqueous phase counted for degraded 125I-LDL. Lipid was extracted from cell 
lysates using Dole reagent (isopropanol/heptane/1M sulfuric acid, 40:10:1) and 
the organic phase counted for 3H by scintillation counting. 
 Cellular 3H (dpm/mg cell protein) was used to quantify total CE uptake 
(nmol CE/mg cell protein). 125I uptake (dpm/mg cell protein, the sum of cell-
associated and degraded 125I) was used to calculate CE uptake equivalents (nmol 
CE/mg cell protein) based on assumption (2) above (whole-particle LDL uptake 
with concomitant CE delivery). In some previous reports, LDL uptake and CE 
uptake were expressed as ng of HDL or LDL protein taken up (115). In this 
project, it was decided that nmol of CE is the preferred unit for both CE uptake 
and LDL uptake, because the amount of CE taken up is the primary point of 
interest and because this value could be compared to net accumulation of 
cholesterol in cells. As per (5), selective CE uptake was calculated as the 
difference between total CE uptake and CE uptake equivalents contributed by 
125I-LDL uptake. In some experiments in which the primary purpose of the 125I 
measurement was to analyze LDL protein uptake (rather than CE uptake), 125I 
data was expressed as µg 125I-LDL protein/mg cell protein. FC uptake was 
determined by the same method in cells treated with [3H]FC/125I-LDL, using  
total FC uptake and FC uptake equivalents from 125I-LDL uptake to calculate the 
selective FC uptake. 
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Measurement of  LDL-derived [3H]CE hydrolysis 
  After treatment in medium B as indicated in Figure Legends, BMMs were 
washed and lipid was extracted from cells (with hexane/isopropanol (3:2)) and 
culture media (with Dole Reagent) and dried under a gentle argon stream. Cell 
lysates and aliquots from culture media were used for determination of 125I 
association, degradation and uptake. Lipid extracts were resuspended in 
chloroform and [3H]CE and [3H]FC were separated by TLC as described above. 
The fraction of 3H dpm in the CE and FC spots was determined for each sample 
and multiplied by the total 3H to determine the amount of [3H]CE and [3H]FC, 
respectively. The amount of [3H]FC already present in the [3H]CE/125I-LDL 
before incubating with cells was determined in each experiment and was 
subtracted as a background during determination of [3H]FC accumulation in the 
culture medium. This background was <5% of total 3H and did not change 
during 37 ˚C incubation in empty wells. Total CE uptake was calculated as the 
sum of [3H]FC and [3H]CE in cells plus the quantity of [3H]FC in the culture 
medium (assumption (4) above). CE uptake equivalents and selective CE uptake 
were determined from 125I-LDL uptake as described for the determination of CE 
uptake. 
 
Statistics and Data Analysis 
  Results are expressed as the mean +/- SEM as indicated in Figure Legends. 
Where not visible, error bars are contained within the symbols for results with 
n≥3. Statistical analysis was done when appropriate using unpaired, two-tailed t-
tests. Best-fit curves were generated using GraphPad Prism4 software. 
 
Copyright © Jason M. Meyer 2013 
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CHAPTER 3: CONTRIBUTION OF SELECTIVE CE UPTAKE TO LDL-
INDUCED MACROPHAGE FOAM CELL FORMATION 
INTRODUCTION 
  As discussed in Chapter 1, macrophage foam cells are a defining 
pathologic feature of atherosclerotic lesions (5). A major characteristic of these 
cells is cholesteryl ester (CE) accumulation within intracellular lipid droplets. 
LDL may play a major role in promoting foam cell formation by acting as a 
cholesterol donor during lipid accumulation. Indeed, high serum LDL is 
correlated with atherosclerosis in humans and experimental animals, and 
treatments that reduce serum LDL can halt progression of the disease and 
reduce complications such as myocardial infarction (60, 136, 137). However, 
there are currently no medications in use that target the macrophage foam cell 
directly and further work is needed to determine the mechanisms responsible for 
macrophage LDL uptake and cholesterol accumulation in vivo (138). 
  Several pathways have been shown to induce cholesterol accumulation in 
cultured macrophages. Classically, scavenger receptor-mediated uptake of 
oxidized or enzyme-modified LDL is cited as a mechanism for foam cell 
formation (139, 140). Scavenger receptor-independent mechanisms are also 
involved in the uptake of some forms of enzyme-modified LDL including 
sPLA2-modified LDL (141). In addition to chemically modified LDL, aggregated 
or matrix-associated LDL promotes cholesterol accumulation by stimulating 
LDL degradation in surface-connected compartments (142). There is evidence 
that various modified LDLs are present in atherosclerotic lesions (7, 143-145) 
but macrophage uptake of these ligands has not been shown to be required for 
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foam cell formation in vivo. More recently, a series of studies have demonstrated 
that native, unmodified LDL induces macrophage lipid accumulation at high 
concentrations (105, 107, 146). This accumulation is dependent on the induction 
of bulk fluid uptake through macropinocytosis and micropinocytosis and is 
independent of LDL binding to the LDL receptor and other cell-surface 
receptors (106, 147). Pinocytosis of LDL-sized nanoparticles was demonstrated 
in atherosclerotic lesions of mice, supporting the potential significance of 
pinocytosis of native LDL during atherogenesis (148). 
  All of the current proposed mechanisms for macrophage foam cell 
formation involve intact (whole-particle) LDL uptake. However, CE and free 
cholesterol (FC) can also be taken up from lipoproteins independently of 
apolipoprotein by a process called selective lipid uptake. The HDL receptor 
scavenger receptor B-I (SR-BI) functions as the major mediator of selective 
uptake from HDL in hepatocytes and steroidogenic cells (89). However, other 
mechanisms have been shown to be involved in selective CE uptake in other cell 
types (149-151). Importantly, macrophages exhibit SR-BI-independent selective 
CE uptake from both HDL and LDL (109-111, 114, 115). Selective lipid uptake 
is enhanced in atherosclerotic lesions of mice, indicating that macrophage 
selective uptake may be important during foam cell formation in vivo (113). 
However, a role for selective CE uptake in macrophage cholesterol accumulation 
from LDL has not been established. The purpose of this section of the 
dissertation project was to characterize macrophage selective CE uptake in 
conditions of foam cell generation, to determine whether this pathway provides 
functional cholesterol to cells, and to quantify the contribution of this pathway 
to excessive cholesterol accumulation induced by LDL. 
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ADDITIONAL MATERIALS AND METHODS  
 
Animals and reagents 
  SR-BI-null mice were obtained from Monty L. Krieger (MIT, Cambridge, 
MA) (152), and were bred together with wild-type control mice from a common 
mating pair of SR-BI heterozygous (SR-BI+/−) mice. CD36-null mice were 
obtained from Roy L. Silverstein (Cleveland Clinic, Cleveland, OH) (153). In this 
chapter, “[3H]CEt” refers [Cholesteryl-1,2-3H(N)]-hexadecyl ether (Perkin 
Elmer) and “[3H]CE” refers to [Cholesteryl 1, 2, 6, 7 H(N)] oleate (American 
Radiolabeled Chemicals). Cytochalasin D, latrunculin B, the ACAT inhibitor CI-
976, chloroquine and diethylumbelliferyl phosphate (UBP) were purchased from 
Sigma, and were added to culture media as a DMSO solution (except 
chloroquine, which was added as an acqeous solution). The final concentration 
of DMSO was <0.1% in all experiments.  
 
Cells 
  RAW, J774 and P388D1 macrophage-like cell lines were cultured by 
standard methods in media C (RPMI 1640 with 10% (v/v) heat-inactivated fetal 
bovine serum (FBS), 50 IU/mL penicillin G and 50 µg/mL streptomycin). Cells 
were passaged when semi-confluent (approximately 75%) by scraping and split 
1:6 (RAW and J774) or 1:2 (P388D1). Experimental treatments using these cell 
lines were carried out as described in Figure Legends in media D (RPMI 1640 
(Gibco) with 0.5% fatty acid-free bovine serum albumin (BSA), 10 mM HEPES 
pH 7.4, 50 IU/mL penicillin G and 50 µg/mL streptomycin). 
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Experimental conditions 
  Treatment of cells at 4 ˚C was carried out by placing the culture cluster 
plate (24 wells) on ice, removing the culture medium under sterile conditions and 
rinsing the cells once with 0.5 mL of ice-cold PBS, then adding ice-cold 
treatment medium (in 200 µL of standard medium B) to each well, then placing 
the covered ice bucket into a 4˚C refrigerator for the indicated time period. 
There was no indication of cell detachment or loss of cell viability during these 
procedures. 
 
RESULTS 
 
Native LDL and macrophage foam cell formation 
  Native LDL has been shown to induce cholesterol accumulation in 
human monocyte-derived macrophages (105). These studies suggested that high 
LDL concentrations (1000 µg/mL LDL or more) are required to induce 
substantial cellular cholesterol accumulation. In the current study, we sought to 
confirm this finding in another model of macrophage foam cells: murine bone 
marrow-derived macrophages (BMMs). 24 h treatment of BMMs with LDL 
(250-1000 µg/mL) resulted in Oil Red-O (ORO)-positive lipid droplet 
deposition (Fig. 3.1A). The number of droplets produced per cell was almost 
linearly related to LDL concentration (Fig. 3.1B), while lipid droplets were not 
observed in cells treated without LDL.  Cholesterol quantification showed that 
cellular total cholesterol (TC) increased in a nearly linear manner with respect to 
LDL concentration, resulting in a 3-fold increase in BMMs treated with 1000 
µg/mL LDL (Fig. 3.1C). Similar to the pattern of ORO-positive lipid droplets, 
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CE was not detected in untreated cells but accumulated in cells treated with LDL 
in a linear manner with respect to LDL concentration.  Free cholesterol (FC) 
accumulation was less pronounced and exhibited saturation, with a near-maximal 
level of free cholesterol observed in cells treated with 250 µg/mL LDL. 
 
Figure 3.1. Foam cell formation in BMMs treated with native LDL. BMMs 
were treated for 24 hr with the indicated concentration of LDL in medium B. 
Cells were then washed and stained with Oil Red-O (A) and the number of lipid 
droplets per cell were quantified (B, shown as the mean +/- SD, n = 30 cells), or 
cell lipids were extracted and used for determination of total cholesterol (TC), 
free cholesterol (FC), and CE content (C, shown as the mean +/- SEM, n=3). 
Results are representative of 4 independent experiments. a, p<0.01 vs. 0 µg/mL 
LDL; b, p<0.01; c, p<0.001; d, p<0.05 vs. 250 µg/mL; e, p<0.01; f, p<0.001; g, 
p<0.01 vs. 500 µg/mL; h, p<0.001 
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  The ability of native LDL to induce foam cell formation was also 
examined in 3 murine macrophage-like cell lines: RAW, J774 and P388D1 (Fig. 
3.2). Nonsaturable LDL-induced lipid droplet formation was observed in RAW 
and J774, with more droplets observed in RAW cells compared to J774 at each 
LDL concentration. P388D1 cells contained lipid droplets when treated without 
LDL, and the presence of LDL induced modest, if any, increase in droplet 
abundance. 
 
Figure 3.2. LDL-induced foam cell formation in macrophage-like cell 
lines. The indicated cells were treated the indicated concentration of LDL in 
medium D for 24 hours, then washed and stained with Oil Red-O to visualize 
neutral lipid droplets. 
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  Together, these results demonstrate that in primary BMMs and in two 
macrophage cell lines, LDL treatment induces foam cell formation. This 
confirms the previous findings using human macrophages and indicates that this 
effect is not species-specific. 
 
Macrophage selective CE uptake from native LDL 
  The previous investigations in human macrophages demonstrated that 
LDL particle uptake contributed to net cholesterol accumulation, but did not 
report measurements of CE or FC uptake and therefore did not rule out the 
possibility that selective lipid uptake contributed as well (105) (106). To 
investigate this possibility in the current investigation, the rates of uptake of LDL 
CE and LDL protein were quantified (Fig. 3.3). This was carried out using 
[3H]CEt/125I dual-labeled LDL (tracers for the CE and protein components of 
LDL, respectively), as previously reported (110). [3H]CEt was used in the intial 
experiments rather than [3H]CE for reasons discussed in Chapter 2. In the initial 
experiments, BMMs were treated with either 10 or 250-1000 µg/mL 
[3H]CEt/125I-LDL in order to compare low concentrations typical in lipoprotein 
uptake experiments (110) to higher concentrations that induce foam cell 
formation (see Fig. 1). Following treatment of macrophages with radiolabeled 
LDL, cellular 3H dpm was used to determine CE uptake (expressed as nmol 
CE/mg cell protein), while 125I was used to calculate CE uptake equivalents 
assuming whole-particle LDL uptake as described in Materials and Methods. 
  At both low (10 µg/mL, Fig. 3.3A-B) and high (250 µg/mL, Fig. 3.3C-E) 
LDL concentrations, total CE uptake in BMMs ([3H]CEt) was significantly 
greater than than the CE contributed by whole-particle uptake (i.e., CE uptake 
equivalents determined from cell-associated and degraded 125I-LDL), indicating 
selective CE uptake from LDL in these cells. The basic finding of macrophage 
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selective CE uptake from LDL was consistently observed in multiple 
experiments using 6 separate LDL preparations, in which selective uptake 
contributed on average ~75-95% of the total CE uptake.  
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Figure 3.3. Macrophage selective LDL CE uptake. BMMs were treated 10 
µg/mL (A-B) or 250 µg/mL (C-D) [3H]CEt/125I-LDL for the indicated time 
periods, or with the indicated concentration of [3H]CEt/125I-LDL in medium B 
for 4 hr (E). Panels B and D are magnifications of panels A and C, respectively 
for clarification. CE uptake was calculated from [3H]CEt and 125I as described in 
Materials and Methods, and selective CE uptake ((3H)-(125I)) was calculated as the 
difference between these two values. (F) BMMs were pre-treated for 24 hr in 
medium A with or without 500 µg/mL LDL or 25 µg/mL acetylated LDL, and 
then washed and treated with 250 µg/mL [3H]CEt/125I-LDL in medium B for 4 
hr. CE uptake was determined from [3H]CEt and 125I and expressed as a percent 
of the control value (pretreated without LDL or acLDL). Values are the mean 
+/- S.E.M. (n=3 except for panel D, n=4). *, p<0.05 compared to 125I or 
control; **, p<0.01; ***, p<0.001. Results are representative of 3 independent 
experiments. 
  LDL CE uptake was further investigated in time course and 
concentration curve experiments (Fig. 3.3A-D). 125I-LDL uptake was constant 
over time, resulting in a linear pattern of accumulation. The majority (>90%) of 
125I taken up was degraded and released from cells within 24 hr (data not shown), 
consistent with a process of whole particle endocytosis and delivery to 
lysosomes. In contrast, [3H]CEt uptake was characterized by a biphasic response 
with a rapid initial rate that decreased over the first 4 hours. [3H]CEt uptake was 
significantly greater than 125I-LDL uptake even at very early time points (5-15 
min). The initial rate of [3H]CEt uptake, also shown in Figs. 3.3B and 3.3D 
(magnifications of Figs. 3.3A and 3.3C, respectively), was 12- and 19-fold greater 
than the initial rate of 125I-LDL CE uptake at 10 and 250 µg/mL LDL, 
respectively (Table 3.1). [3H]CEt uptake was linearly proportional to the LDL 
concentration and did not exhibit saturability between 250 and 1000 µg/mL 
LDL (Fig. 3.3E). As the LDL concentration increased, the ratio of [3H]CEt to 
125I-LDL uptake increased from 3.5:1 at 250 µg/mL LDL to more than 8:1 at 
1000 µg/mL LDL, due to partial saturation of the 125I-LDL uptake process. 
These results provide strong evidence that selective CE uptake is a major 
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contributor to total CE uptake from LDL at both low and high LDL 
concentrations. 
 
Initial Rates 10 µg/mL 
LDL 
250 µg/mL 
LDL 
[3H]CEt 
uptake 
(nmol CE/mg 
cell protein/hr) 
2.271  ± 
0.782791 
37.7163 ± 
5.4087 
125I-LDL 
uptake 
(nmol CE/mg 
cell protein/hr) 
0.1871 ± 
0.001936 
 
1.960 ± 
0.06130 
p value 0.00748 0.001269 
 
 
Table 3.1. Initial rates of [3H]CEt uptake and 125I-LDL uptake. Calculated 
from the best-fit curves from Fig. 3.3A and 3.3C. 
Effect of  cholesterol loading on selective CE uptake 
  In many cells, cellular cholesterol content is controlled by the coordinate 
regulation of lipoprotein uptake, cholesterol synthesis and cholesterol efflux. 
Therefore we tested whether prior cholesterol loading might affect CE uptake 
from LDL (Fig. 3.3F). Cholesterol accumulation was induced by pre-treating 
cells for 24 hr with 500 µg/mL LDL (shown to cause cholesterol accumulation 
in Fig. 3.1), or 25 µg/mL acetylated LDL (acLDL). However, cholesterol loading 
did not lead to a reduction in [3H]CEt or 125I-LDL uptake, both of which 
increased in cholesterol-loaded cells. 
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Comparison of  CE uptake and FC uptake from LDL 
  Uptake of LDL [3H]CEt was also compared to [3H]CE and [3H]FC to 
further characterize macrophage LDL metabolism (Fig. 3.4). There are no 
published reports of FC uptake or selective FC uptake from LDL in 
macrophages. [3H]CE uptake was similar to uptake of [3H]CEt, suggesting that 
[3H]CEt is a valid marker for LDL CE uptake (Fig. 3.4A). In contrast, [3H]FC 
uptake was ~10-fold lower than [3H]CEt or [3H]CE uptake (Fig. 3.4A). In 
addition, macrophage [3H]FC accumulation was almost completely accounted 
for by whole-particle 125I-LDL uptake, with little or no selective FC uptake (Fig. 
3.4A-B). Selective uptake of CE but not FC from LDL was observed in several 
experiments at LDL concentrations ranging from 250 to 1000 µg/mL LDL (data 
not shown). These results demonstrate that selective CE uptake represents the 
major pathway of cholesterol uptake during foam cell formation from LDL, with 
smaller amounts of supplied by the CE and FC acquired by whole-particle LDL 
uptake. 
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Figure 3.4. Comparison of CEt, CE and FC uptake from LDL. BMMs were 
treated with 250 µg/mL of [3H]CEt/125I-LDL, [3H]CE/125I-LDL or [3H]FC/125I-
LDL in medium B for the indicated time period. LDL CE or FC uptake was 
determined from cell-associated 3H (A) and LDL FC uptake was determined 
from [3H]FC and 125I-LDL uptake (B) as described in Materials and Methods. 
Values are the mean +/- S.E.M. (n=3). *, p<0.05 compared to the 
corresponding 125I-LDL value; **, p<0.01. Results are representative of 3 
independent experiments. 
 
Selective CE uptake in murine peritoneal macrophages (MPMs) and in 
macrophage cell lines 
  Selective CE uptake from LDL was also observed in cultured peritoneal 
macrophages (MPMs, Fig. 3.5A), and to a lesser extent, in J774 and RAW cells 
(Fig. 3.5B-C). In contrast, selective uptake was not detected in P388D1 cells 
across the LDL concentration range tested (Fig. 3.5D). Differences in the 
amount of CE uptake did not appear to explain the differences in lipid 
deposition in these cells (as shown in Fig. 3.2), suggesting that other factors, 
including possibly FC efflux or ACAT-mediated FC esterification, may differ 
between these cell types. 
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Figure 3.5. Selective CE uptake in MPMs and macrophage-like cell lines. 
MPMs (A) or the indicated cell type (B-D) were treated with 500 µg/mL of 
[3H]CEt/125I-LDL in medium B (A) or medium D (B-D) for 4 hr. CE uptake 
was calculated from [3H]CEt and 125I as described in Materials and Methods, and 
selective CE uptake ((3H)-(125I)) was calculated as the difference between these 
two values. Values are the mean +/- S.E.M. (n=3 except A, n=4). *, p<0.05 
compared to the corresponding 125I-LDL value; **, p<0.01; ***, p<0.001. 
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Role of  actin polymerization-dependent pinocytosis in selective CE 
uptake 
  The experiments described above (Figs. 3.3-3.5) provide quantitative 
evidence for selective CE uptake in macrophages. However, these data do not 
demonstrate that the mechanism of selective CE uptake is distinct from that of 
whole particle LDL uptake. 
  To test this, inhibitors of LDL particle uptake were employed. 
Macrophage LDL endocytosis during foam cell formation was previously shown 
to be dependent on fluid-phase pinocytosis and was inhibited by cytochalasin D, 
an inhibitor of actin polymerization (106). Actin polymerization is required for 
macropinosome formation. Inhibition of actin-dependent pinocytosis in BMMs 
by cytochalasin D was confirmed by showing that it blocked 125I-BSA uptake (a 
marker of fluid-phase pinocytosis) by >65% (Fig. 3.6A). Cytochalasin D also 
blocked 125I-LDL uptake by >75%, but had a more modest effect on selective 
[3H]CEt uptake (<35% inhibition) (Fig. 3.6B). In three independent experiments 
cytochalasin D reduced 125I-LDL uptake by 62.5 ± 13.5% and selective [3H]CEt 
uptake by 27.6 ± 8.6%, a difference that was statistically significant (p<0.05). 
This distinct pattern of inhibition was also conserved at a range of LDL 
concentrations (Fig. 3.6C-D). A similar result was obtained with 1 µg/mL 
Latrunculin B, another inhibitor of actin polymerization (Fig. 3.6E). Lower 
concentrations of latrunculin B affected both LDL uptake and selective CE 
uptake similarly, consistent with differences that have been reported for the 
effective concentration range of latrunculin B compared to cytochalasin D (154). 
Nonetheless, as selective CE uptake was inhibited no more than ~35% in any 
experiment, the results obtained with these two inhibitors indicated that selective 
CE uptake from LDL is largely independent of actin polymerization and fluid-
phase pinocytosis. 
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Figure 3.6. Role of actin polymerization in selective LDL CE uptake. A, B. 
BMMs were pre-treated for 30 minutes with the indicated concentration of 
cytochalasin D in medium A, then washed and treated for 4 hours with the same 
addition of cytochalasin D plus 50 µg/mL 125I-BSA (A) or 500 µg/mL 
[3H]CEt/125I-LDL (B) in medium B. 125I-BSA (A) or 125I-LDL and selective 
[3H]CEt uptake (B) were determined as described in Materials and Methods. C, D. 
BMMs were pre-treated for 30 minutes with 2 µg/mL of cytochalasin D in 
medium A, then washed and treated for 4 hours with the same addition of 
cytochalasin D plus the indicated concentration of [3H]CEt/125I-LDL in medium 
B. Selective [3H]CEt uptake (C) and 125I-LDL uptake (D) were determined as 
described in Materials and Methods. E. BMMs were pre-treated for 30 minutes 
with the indicated concentration of latrunculin B in medium A, then washed and 
treated for 4 hours with the same addition of latrunculin B plus 500 µg/mL 
[3H]CEt/125I-LDL in medium B. Selective [3H]CEt uptake and 125I-LDL uptake 
were determined as described in Materials and Methods. Values are the mean of 
duplicate determinations (A, B and E) or are the mean +/- S.E.M. (n=3, in C 
and D). Results are representative of 3 independent experiments. 
 
Contribution of  scavenger receptor B-I (SR-BI) and CD36 to 
macrophage selective CE uptake 
  The Class B scavenger receptors SR-BI and CD36 bind native LDL in 
addition to HDL and modified LDL and have been shown to mediate selective 
CE uptake in other cell types (89, 155-157). However, we recently showed that in 
BMMs selective CE uptake from HDL occurs independent of SR-BI. Likewise 
in the current study, CE uptake from LDL was not impaired in a time course 
with BMMs from SR-BI-deficient mice (Fig. 3.7A-C). In a separate experiment at 
a lower LDL concentration (10 µg/mL, chosen to maximize the contribution of 
high-affinity receptors to total CE uptake), deficiency of SR-BI, CD36 or both 
did not result in reduced LDL CE uptake (Fig. 3.7D). Therefore, these receptors 
are unlikely to be involved in the LDL selective CE uptake pathway in BMMs. 
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Figure 3.7. Role of class B scavenger receptors in macrophage selective 
CE uptake. A. BMMs from WT or SR-BI-null mice were treated with 100 
µg/mL [3H]CEt/125I-labeled LDL for the indicated and CE uptake (A), CE 
uptake equivalents from LDL uptake (B) and selective CE uptake (C) were 
determined as described in Materials and Methods. D. BMMs from WT, SR-BI-
null, CD36-null or DKO mice were treated with 10 µg/mL [3H]CEt/125I-LDL 
for 4 hours and CE uptake determined as described in Materials and Methods. 
Values are the mean +/- S.E.M. (n=3). Results from A-C are representative of 2 
independent experiments. 
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LDL CE hydrolysis 
  CE derived from lipoproteins through endocytosis is typically hydrolyzed 
and incorporated into cellular cholesterol pools before it can be re-esterified in 
lipid droplets (139). However, it is not known whether CE derived selectively 
from LDL is hydrolyzed in macrophages. Results from other experiments (Figs. 
3.3-3.7) characterized the uptake of CE from LDL but did not discriminate 
between [3H]CE and [3H]FC that may have been formed by hydrolysis or 
esterification within cells. To assess this, [3H]CE was used rather than [3H]CEt to 
allow cellular hydrolysis (as described in Chapter 2). 
  Thin-layer chromatography (TLC, procedure also described in Chapter 2) 
revealed that during 2-24 h treatment of BMMs with 250 µg/mL (Fig. 3.8, left 
panels) or 1000 µg/mL (Fig. 3.8, right panels) [3H]CE/125I-LDL, the majority of 
cell-associated 3H accumulated as [3H]FC (Fig. 3.8A). This indicated that 
macrophages hydrolyzed the majority of CE taken up from LDL. CE hydrolysis 
was cell-mediated since [3H]FC was not generated when media containing 
[3H]CE-LDL was incubated in empty wells without BMMs (data not shown). 
[3H]FC accumulated in cells more rapidly at 1000 µg/mL LDL compared to 250 
µg/mL, and reached a higher concentration before coming to a plateau. [3H]FC 
was also detected in the treatment medium (Fig. 3.8B) and accumulated in a 
linear pattern with time, again more rapidly in cells treated at 1000 µg/mL. After 
24 hr, the amount of [3H]FC in the culture medium was nearly equal to (250 
µg/mL LDL) or greater than (1000 µg/mL LDL) the amount present in cells 
(Fig. 3.8C), indicating that a significant portion of the formed [3H]FC was 
effluxed from cells. 
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Figure 3.8. LDL CE uptake and hydrolysis. BMMs were treated with 250 
µg/mL (A, C, and E) or 1000 µg/mL (B, D, and F) [3H]CE/125I-LDL for the 
indicated time period, then lipid was extracted from cells (A-B) and media (C-D) 
and separated by TLC. [3H]CE and [3H]FC were quantified as described in 
Materials and Methods. In the same experiment, CE uptake was determined from 
the total cellular 3H (cells) and the from the sum of the cellular 3H and the 
[3H]FC accumulated in the culture media (cells+media) (E  and F), as described 
in Materials and Methods. Values are the mean +/- S.E.M. (n=3). Results are 
representative of 2 independent experiments. 
  Treatment of cells at reduced temperature (e.g. 4 ˚C) is often utilized in 
studies of receptor-mediated endocytosis to allow binding but not internalization 
of radiolabeled ligands in order to study the sequence of ligand uptake (133). 
BMMs treated with 50 µg/mL [3H]CE/125I-LDL at 4 ˚C (Fig. 9A) took up 
[3H]CE at a reduced rate (~8-fold) compared to cells treated at 37 ˚C (Fig. 3.9B). 
However, 125I-LDL uptake was reduced more than 100-fold, so that the [3H]CE 
taken up at 4 ˚C was almost entirely contributed by selective CE uptake. Analysis 
of cell lipids by TLC indicated that cell-associated [3H]CE was modestly reduced 
(Fig. 3.9C) while the generation of cell-associated [3H]FC was almost entirely 
inhibited (Fig. 3.9D). In a separate experiment, similar results were obtained with 
BMMs treated with 250 µg/mL [3H]CE/125I-LDL (Fig. 3.9E). Therefore, 
selective CE uptake and the hydrolysis of LDL-derived CE are inhibited at 4 ˚C, 
although some residual selective CE uptake occurs at this reduced temperature. 
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Figure 3.9. Effect of reduced temperature on LDL CE uptake and 
hydrolysis. BMMs were treated with 50 µg/mL (A-D) or 250 µg/mL (E) 
[3H]CE/125I-LDL at the indicated temperature for the indicated time period. CE 
uptake was calculated from [3H]CE and 125I as described in Materials and Methods, 
and selective CE uptake ((3H)-(125I)) was calculated as the difference between 
these two values (A, B and E).  In the same experiment, lipid was extracted from 
cells and separated by TLC (C-E). [3H]CE and [3H]FC were quantified as 
described in Materials and Methods. Values are the mean +/- S.E.M. (n=3). Results 
are representative of 2 independent experiments. statistics 
  
Involvement of  acid and neutral lipase activity in LDL CE hydrolysis 
  The next major experimental question regarded the mechanism by which 
cells hydrolyzed the CE following selective CE uptake. CE hydrolysis is 
catalyzed in cells by acidic lipase in lysosomes (134) and/or neutral cholesteryl 
esterase (nCEase) in the cytoplasm and other cellular compartments (158). 
Therefore, pharmacologic inhibitors of each of these processes were employed 
in the current study, and each was tested to confirm the expected effect before 
being used to study LDL-derived CE hydrolysis. 
  Chloroquine has been used for many years to study lysosome function 
(159). It is a weak base that accumulates in lysosomes and blocks the function of 
this organelle by increasing the intralysosomal pH. Macrophage LDL 
apolipoprotein degradation (measured as µg 125I-LDL protein/mg cell protein) 
involves acid proteases and is inhibited by chloroquine (160). In the current 
study, inhibition of LDL degradation in BMMs was confirmed by treatment with 
up to 200 µM of chloroquine and measurement of 125I-LDL degradation (Fig. 
3.10A). 200 µM of chloroquine was necessary to inhibit the majority of 125I-LDL 
degradation in BMMs. 
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  The major established role of nCEase is the hydrolysis of CE contained 
in cytoplasmic lipid droplets (161), which is blocked by diethylumbelliferyl 
phosphate (UBP) (158). In previous experiments, 200-400 µM of UBP was 
required to completely block nCEase activity. To confirm that lipid droplet 
hydrolysis was blocked by UBP, BMMs were pulsed for 24 h with 500 µg/mL of 
LDL in the presence of 0.2 µCi/mL [3H]FC to label cellular cholesterol pools 
including lipid droplet CE (Fig. 3.10B). After the treatment, a portion of the 
[3H]FC associated with cells had been converted into [3H]CE (Fig. 3.10B, left 
bar). The cells were then washed and chased for 24 h with unlabeled HDL to 
promote lipid droplet mobilization by stimulating cholesterol efflux from cells, 
without or with the addition of 400 µM UBP. HDL induced a significant 
reduction in cell [3H]CE during the chase period, indicating CE hydrolysis, but 
UBP blocked this effect, confirming that UBP is an effective inhibitor of neutral 
esterases in BMMs. 
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Figure 3.10. Effect of chloroquine and UBP on CE uptake and hydrolysis. 
A. BMMs were pretreated for 2 hr in medium A with or without the indicated 
concentration of chloroquine, then treated with the same conditions plus 250 
µg/mL [3H]CE/125I-LDL for 4 hr, and 125I-LDL degraded during the treatment 
period was determined as described in Materials and Methods. B. BMMs were 
pretreated for 24 hr in medium A with 500 µg/mL LDL and 0.2 µCi/mL 
[3H]FC, then washed thoroughly and chased with medium A and the indicated 
addition of HDL (100 µg/mL) and /or UBP (400 µM) for 24 hours, and cell 
lipid was extracted and separated by TLC and [3H]CE quantified as described in 
Materials and Methods. C, D. BMMs were pretreated for 2 hr in medium A with or 
without 200 µM chloroquine (chlor) or 400 µM diethylumbelliferyl phosphate 
(UBP), then washed and treated with the same conditions in medium B plus 250 
µg/mL [3H]CE/125I-LDL for 4 hr. Cells were then washed thoroughly and media 
and cell lysates were collected and used for determination of 125I-LDL uptake, 
association and degradation as described in Materials and Methods (C). Cell lipid 
was extracted and separated by TLC and [3H]CE and [3H]FC were quantified as 
described in Materials and Methods (D). Values are the mean +/- S.E.M. (n=3 for 
A and B, and n=4 for C and D). Results in panels C and D are representative of 
3 independent experiments. *, p<0.05 compared to control; *, p<0.01; ***, 
p<0.001. 
  After confirming that in BMMs chloroquine and UBP can inhibit 
lysosome and neutral CE hydrolysis activity, respectively, the ability of these 
inhibitors to block LDL CE metabolism relevant to the selective CE uptake 
pathway was compared (Fig. 3.10C-D). The LDL particle uptake and 
degradation pathway, known to be inhibited by chloroquine, was analyzed in the 
same experiment (Fig. 3.10C). Chloroquine significantly reduced 125I-LDL 
degradation and concomitantly increased cell-associated 125I-LDL within BMMs 
(Fig. 3.10C), as expected (160). Similar to the effect on 125I-LDL degradation, 
chloroquine almost completely inhibited the generation of [3H]FC in cells treated 
with [3H]CE/125I-LDL (Fig. 3.10D). However, unlike 125I-LDL uptake, total 
[3H]CE uptake was also significantly reduced by chloroquine. In contrast to 
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chloroquine, the neutral cholesteryl esterase inhibitor UBP had no effect on 
LDL degradation and only a modest effect on [3H]CE uptake and hydrolysis 
(Fig. 3.10C and 3.10D, respectively). 
  These data implicated the involvement of acid but not neutral hydrolase 
activity in LDL-derived CE hydrolysis during foam cell formation. In addition to 
blocking CE hydrolysis, chloroquine also inhibited CE uptake but not LDL 
particle uptake, supporting the hypothesis that a portion of CE is taken up from 
LDL by a mechanism that is distinct from the 125I-LDL endocytosis and 
lysosomal delivery pathway. 
 
Temporal sequence of  LDL-derived CE hydrolysis in pulse-chase 
studies 
  Since [3H]CEt uptake was not significantly less than [3H]CE uptake in 
previous experiments (see Fig. 3.8A), it was expected that CE hydrolysis and 
efflux occurred after uptake into cells. To confirm this, macrophages were 
pulsed for 30 min with 250 µg/mL [3H]CE/125I-LDL, washed thoroughly and 
chased with unlabeled LDL (Fig. 3.11). A short pulse period (30 min) was used 
because at this early time point the amount of cell-associated [3H]CE was greater 
than [3H]FC (Fig. 3.11A, 0 h time point). LDL-derived [3H]CE diminished 
rapidly during the chase period with a half time of about 30 min and this was 
accompanied by an increase in [3H]FC in both cells (Fig. 3.11A) and culture 
medium (Fig. 3.11B). The estimated rate of efflux of [3H]FC was ~13.5% of total 
cellular 3H in 4 hr, similar to the rate observed in cells treated continuously with 
[3H]CE/125I-LDL (Fig. 3.8B, ~50% in 24 hr), indicating that efflux of cell-
associated [3H]FC may account for the appearance of [3H]FC in the culture in 
the previous experiment. [3H]CE release was not detected in any experiment. In 
a second experiment in which cells were pulsed overnight with [3H]CE-LDL at 
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4˚C (as described in Fig. 3.9), cell-assocated [3H]CE was converted into [3H]FC 
when cells were warmed to 37 ˚C, and this hydrolysis was almost completely 
prevented by the addition of chloroquine to the chase media (Fig. 3.11C). These 
data indicated that CE hydrolysis occurs subsequent to uptake into cells, and 
confirms the involvement of acid lipase activity in LDL-derived CE hydrolysis. 
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Figure 3.11. LDL-derived CE hydrolysis and efflux. A, B. BMMs were 
treated for 30 min in medium B with 250 µg/mL [3H]CE/125I-LDL and then 
washed thoroughly and chased with 250 µg/mL unlabeled LDL in medium B for 
the indicated time period, after which lipid was extracted from cells (A) and 
media (B) and [3H]CE and [3H]FC quantified as described in Materials and 
Methods. C. BMMs were treated at 4 ˚C with 250 µg/mL [3H]CE/125I-LDL for 16 
hr, then washed thoroughly and chased with medium B with or without 200 µM 
chloroquine. Cell lipid was extracted and the % [3H]CE of total cellular 3H 
quantified as described in Materials and Methods. Values are the mean +/- S.E.M. 
(n=3). Results are representative of 2 independent experiments. ***, p<0.001 
compared to control. 
 
ACAT-dependent re-esterification of  cholesterol derived from LDL CE 
  In the classic model of foam cell formation, CE-rich cellular lipid 
droplets are generated by ACAT-mediated FC esterification (162). To test 
whether CE accumulation and lipid droplet deposition occurring during LDL 
treatment was due to ACAT activity, BMMs were treated for with LDL (500 
µg/mL) for 24 hours with or without the ACAT inhibitor CI-976 and stained 
with Oil Red-O to visualize lipid droplets (Fig. 3.12A-B). In this experiment, 
acetylated LDL (acLDL, 100 µg/mL) was included as a positive control, known 
to induce macrophage lipid droplet formation in an ACAT-dependent manner. 
As expected, acLDL-induced lipid droplet formation was almost completely 
blocked by CI-976 (Fig. 3.12A-B, see panel B for high magnification). 
Surprisingly, CI-976 did not appear to block the formation of lipid droplets in 
BMMs treated with native LDL, suggesting a major difference compared to 
acLDL. 
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Figure 3.12. Role of ACAT in LDL-induced CE accumulation. A, B. BMMs 
were treated with the indicated addition of 100 µg/mL acLDL or 500 µg/mL 
LDL with or without 10 µg/mL of CI-976 for 24 hr, then washed and stained 
with Oil Red-O to visualize neutral lipid droplets. Images were captured at low 
(A) and high (B) magnification. Results are representative of 2 independent 
experiments. 
  The role of ACAT in LDL-induced CE accumulation was also tested by 
treating cells with 1000 µg/mL [3H]CE-LDL with or without CI-976 and 
measuring the cellular content of [3H]CE (Fig. 3.13A) and [3H]FC (Fig. 3.13B). 
Consistent with the lack of apparent effect on LDL-induced lipid droplet 
deposition (Fig. 3.12A-B), CI-976 did not prevent accumulation of [3H]CE in 
cells during treatment with [3H]CE-LDL (Fig. 3.13A), suggesting that ACAT-
mediated re-esterification is not required for LDL-derived CE accumulation. CI-
976 also did not affect total CE uptake or CE hydrolysis, as the amount of cell-
associated [3H]FC was not altered by this treatment (Fig. 3.13B). There results 
clearly suggest a distinct, ACAT-independent mechanism of CE accumulation 
induced by native LDL. 
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Figure 3.13. Role of ACAT in LDL-induced CE accumulation. A, B. BMMs 
were treated with 1000 µg/mL of  [3H]CE/125I-LDL  with or without 10 µg/mL 
of CI-976 for the indicated time period, then cell lipids were extracted and 
[3H]CE and [3H]FC quantified as described in Materials and Methods. Values are 
the mean +/- S.E.M. (n=3) and results are representative of 2 independent 
experiments. 
 
Effect of  LDL modification and scavenger receptor deficiency on 
selective CE uptake 
  Physical or chemical modification of LDL enhances its binding and 
degradation by macrophages (61, 163), as described in Chapter 1. To study the 
effect of LDL modification on selective CE uptake, BMMs were treated with 
native or modified LDL as previously described (140) using low concentrations 
(10 µg/mL) to study the high-affinity interactions known to be involved in 
macrophage uptake of modified LDL (Fig. 3.14A). Consistent with previous 
reports, we found that endocytosis of acetylated or aggregated LDL (acLDL or 
agLDL, respectively) as measured by 125I was greatly increased compared to 
native LDL (Fig. 3.14A). 125I-LDL uptake was enhanced approximately 7- and 
16-fold by aggregation or acetylation of LDL, respectively. However, compared 
to native LDL, the relative contribution of selective CE uptake from modified 
LDL was either largely abolished (agLDL) or significantly reduced (acLDL). 
Thus, selective CE uptake represents only a minor component of high-affinity 
macrophage cholesterol uptake from modified LDL.  
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Figure 3.14. Effect of LDL modification on selective CE uptake. A. BMMs 
were treated with 10 µg/mL [3H]CEt/125I-labeled LDL, aggregated LDL 
(agLDL) or acLDL for the for 4 hr in medium B and CE uptake, CE uptake 
equivalents from LDL uptake and selective CE uptake were determined as 
described in Materials and Methods. B-D. BMMs were treated with 500 µg/mL 
[3H]CE/125I-LDL or 25 µg/mL [3H]CE/125I-acLDL for 24 h in medium B. TC, 
FC and CE content (B), CE uptake and LDL uptake and selective CE uptake 
(C) and the quantity of [3H]FC accumulation in the culture medium (D) were 
determined as described in Materials and Methods. Values are the mean +/- S.E.M. 
(n=4 except A, n=3). a, p<0.05 compared with the corresponding [3H]CEt from 
the same ligand; b, p<0.05 compared with LDL [3H]CEt; c, p<0.001 compared 
with LDL 125I; d, p < 0.001 compared with LDL [3H]CEt. *, p<0.05 compared 
to control (B), [3H]CE (C), or LDL (D); **, p<0.05; ***, p<0.001. Results from 
B-D are representative of 2 independent experiments. 
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  Different modes of CE uptake between native and modified lipoproteins 
may influence the route of CE trafficking and the possible function of each 
pathway. It was therefore of interest to compare LDL and acLDL metabolism 
under similar, foam cell-inducing conditions. This was investigated in an 
experiment (Fig. 3.14B-D) in which the concentrations of native LDL (500 
µg/mL) and acLDL (25 µg/mL) were matched to induce similar levels of cellular 
FC and CE accumulation (Fig. 3.14B). As described for other experiments, 
selective CE uptake, LDL uptake and CE hydrolysis and efflux were measured. 
At these concentrations, the amount of 125I-LDL or 125I-acLDL uptake over the 
24 h treatment period were similar, but the amount of selective CE uptake was 
much higher with nLDL (Fig. 3.14C). However, the rate of efflux of [3H]FC 
derived from the hydrolysis of LDL-derived [3H]CE was also much higher with 
nLDL (Fig. 3.14D). Therefore, in conditions of equal cholesterol loading over 24 
h, nLDL metabolism is characterized by a much greater amount of flux through 
macrophages in which LDL-derived CE is hydrolyzed and effluxed back into the 
culture medium, while acLDL-derived CE remains trapped within cells. 
 
 
DISCUSSION 
  Atherosclerosis is associated with elevated plasma LDL cholesterol levels, 
often more than 150 mg/dL LDL-C (greater than 1000 µg/mL LDL). As 
discussed in Chapter 1, LDL accumulates at even higher levels in the arterial 
intima where foam cells develop (45, 164). Therefore, studies of lipoprotein 
receptors carried out at very low lipoprotein concentrations may not accurately 
reflect disease conditions related to atherosclerosis and could have led to an 
underestimation of the role of native LDL in foam cell formation (139). In the 
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current investigation, we observed that high concentration LDL induces foam 
cell formation in murine BMMs and several common macrophage cell lines, 
similar to previous reports in human macrophages (105). As described in the 
earlier studies, lipid accumulation from native LDL is a low-affinity process, with 
lipid droplet formation occurring at 250-1000 µg/mL LDL or higher (Fig. 3.1). 
These results support the hypothesis that during hyperlipidemia, native LDL 
may directly contribute to macrophage cholesterol accumulation. 
  The initial goal of the current study was to define macrophage CE uptake 
during lipid accumulation from native LDL. Previous investigations 
demonstrated that LDL particles are taken up and degraded by macrophages as 
part of receptor-independent pinocytosis (106), but these reports did not 
quantify CE uptake and therefore did not address the possible contribution of 
selective CE uptake to cholesterol accumulation induced by native LDL. Our 
results demonstrate that the majority of cholesterol taken up from LDL is 
acquired by selective CE uptake in excess of LDL pinocytosis and degradation. 
Specifically, a traditional endocytic model cannot explain the following 
observations: 1) The quantity of [3H]CEt or [3H]CE uptake was not accounted 
for by 125I-LDL whole-particle uptake, 2) [3H]CEt and [3H]CE uptake were 10 
times greater than [3H]FC uptake, 3) the kinetics and concentration dependence 
of [3H]CEt uptake differed from 125I-LDL uptake and 4) [3H]CEt uptake was 
largely resistant to inhibition by cytochalasin D in comparison to 125I-LDL 
uptake. Together these results provide strong evidence that a distinct selective 
CE uptake pathway contributes to macrophage cholesterol uptake from LDL. 
  This is the first demonstration of selective CE uptake during macrophage 
foam cell formation. Results therefore extend previous observations of 
macrophage selective CE uptake from LDL (110, 111) and emphasize that 
macrophage selective CE uptake is predominantly a low-affinity, high capacity 
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process. The current results also demonstrate that macrophage selective CE 
uptake from LDL is independent of scavenger receptors, in line with earlier 
studies in which we and others demonstrated that selective CE uptake from 
HDL does not require these receptors (114, 115). Macrophage selective CE 
uptake was previously reported to be down-regulated by cholesterol loading 
(111); however, we found that prior cholesterol loading did not reduce selective 
CE uptake. Rather, [3H]CEt accumulated with time in a non-saturating, linear 
manner during foam cell formation. This difference could be because cholesterol 
accumulation was induced in the previous study by ACAT inhibition or 
cholesterol-saturated methyl-β-cyclodextrin, while the current study used native 
or acetylated LDL. Cholesterol accumulation from lipoproteins including native 
LDL is likely to be more relevant to the regulation of macrophage selective 
uptake than the treatments used previously. In addition, several reports indicated 
that selective CE uptake may be a bidirectional exchange process in 
macrophages and other cell types (98, 165), but the current results demonstrate 
that after transfer to macrophages, CE is efficiently hydrolyzed and not released 
into the medium as CE. This difference could be due to the much lower LDL 
concentrations used in previous studies reporting bidirectional selective CE 
uptake, or to differences in the reversibility of [3H]CEt (used in a previous study 
(98)) and [3H]CE. 
  In order to further characterize the selective CE uptake pathway in 
macrophages, we studied subsequent metabolism of LDL-derived CE.  Our 
results demonstrate that after uptake from LDL, CE is rapidly hydrolyzed by 
macrophages, similar to a previous description of macrophage metabolism of 
acetylated LDL (139), but not to oxidized (166) or aggregated (167) LDL, which 
were reported to be resistant to CE hydrolysis. As already mentioned, cell-
associated [3H]CE was not directly released into the chase medium in pulse-chase 
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experiments. These findings are important because they demonstrate that 
[3H]CE uptake is a unidirectional process and not a reflection of simple radio-
isotope exchange resulting from a reversible CE uptake process. Irreversible, 
unidirectional CE uptake suggests cellular internalization. While endocytosis of 
LDL particles could not account for CE uptake in this study, it is possible that 
one or more endocytic processes are involved in the selective CE uptake 
mechanism. One possibility is that CE is first transferred from LDL to the 
macrophage plasma membrane and subsequently sequestered and internalized 
within the membranes of endocytic vesicles. In support of this, LDL [3H]CE 
hydrolysis was almost completely inhibited by chloroquine (>90%) and by 
incubation at 4˚C (>95% inhibition). On the other hand, the neutral lipase 
inhibitor UBP did not substantially reduce [3H]CE hydrolysis, in contrast to a 
previous report investigating SR-BI-directed HDL CE hydrolysis (168).  
  ACAT-mediated cholesterol esterification is thought to be responsible 
for the development of cellular lipid droplets during macrophage foam cell 
formation (162). However, initial results presented in this chapter indicate that 
CE accumulation during LDL treatment occurs independently of ACAT. The 
localization and trafficking of CE in the selective CE uptake pathway is not 
known, but it is possible that in contrast to the canonical hydrolysis-
reesterification model of lipoprotein CE metabolism, foam cell formation with 
native LDL involves direct CE deposition. While the current results indicate that 
most LDL-derived CE is hydrolyzed, the remaining unhydrolyzed fraction may 
constitute the form that accumulates in lipid droplets. Further experiments are 
necessary to test this hypothesis and to fully characterize the selective CE uptake 
pathway in these cells. 
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  One limitation of the current study was that it was not possible to 
distinguish cholesterol derived from LDL endocytosis from that acquired by 
selective CE uptake. While providing less cholesterol to macrophages than 
selective CE uptake, whole-particle uptake of LDL could theoretically contribute 
enough cholesterol to account for the observed CE accumulation induced by 
LDL, assuming markedly different trafficking of cholesterol compared to the 
selective CE uptake pathway. In other words, it is possible that most of the 
cholesterol acquired via whole particle uptake remains within the cell while all or 
nearly all of that acquired via selective CE uptake is effluxed. There is no 
evidence that this is the case; nonetheless, the results in this chapter do not rule 
out the possibility that cholesterol derived from pinocytic uptake of LDL 
particles is solely responsible for foam cell formation during treatment with LDL 
as previously proposed (106). Strategies for specific pharmacologic and/or 
genetic inhibition of LDL selective CE uptake are needed to confirm the 
contribution of this pathway to macrophage foam cell formation. 
  Our results demonstrate rapid efflux of cholesterol generated from 
hydrolysis of LDL-derived CE. Substantial LDL-dependent cholesterol efflux 
was observed in time course and pulse-chase experiments using [3H]CE/125I-
LDL. Efflux of cholesterol during treatment with LDL provides an explanation 
for our observation that net cholesterol accumulation was less than predicted 
from [3H]CEt uptake (compare Figs. 3.1 and 3.3). These results demonstrate that 
an accurate determination of the rate of CE uptake requires consideration of the 
magnitude of FC efflux, especially at relatively high LDL concentrations.  
  In addition to controlling cellular cholesterol content, macrophage 
cholesterol efflux is recognized as a key step in reverse cholesterol transport and 
may impact the removal of cholesterol from atherosclerotic lesions (169, 170). It 
was previously reported that LDL-derived cholesterol is more efficiently released 
 
 
77 
from macrophages than acetylated LDL-derived cholesterol, a finding attributed 
to distinct intracellular trafficking of internalized lipoproteins (171). The current 
results suggest that the greater efflux of cholesterol derived from LDL CE is 
more likely related to differences between the selective CE uptake pathway and 
the classic endocytic pathway. During matched loading conditions, BMMs 
hydrolyzed and effluxed 25 times more CE from LDL compared to acLDL. 
While selective CE uptake may promote macrophage cholesterol accumulation, 
it is interesting to consider that this process may also facilitate reverse cholesterol 
transport by linking LDL CE hydrolysis to cholesterol efflux to HDL and other 
extracellular acceptors. On the other hand, remodeling of lesion-retained LDL 
via selective CE uptake, hydrolysis and efflux may also lead to the generation of 
the FC-rich extracellular lipid particles observed in atherosclerotic lesions, as 
discussed in Chapter 1. 
  The results of this chapter clearly demonstrate that the selective CE 
uptake pathway is an important mode of macrophage cholesterol acquisition 
from LDL. We show that selective CE uptake contributes the majority of 
cholesterol to BMMs during treatment with high concentrations of native LDL. 
In this pathway, CE is rapidly hydrolyzed in a chloroquine-sensitive manner, and 
contributes to cellular FC and CE accumulation. The selective CE uptake 
pathway is characterized by ACAT-independent CE accumulation, as well as a 
high rate of FC efflux. This pathway may play a major role in foam cell 
formation and LDL metabolism in atherosclerotic lesions. 
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CHAPTER 4: EFFECT OF LDL OXIDATION ON MACROPHAGE 
SELECTIVE CE UPTAKE 
 
INTRODUCTION 
 
  Atherosclerotic lesions are defined as lipid-rich plaques in the intima of 
susceptible arteries (172). This lipid is predominantly cholesterol and its esters 
and is localized both within cells (foam cells) and in the extracellular space (27). 
Low-density lipoprotein (LDL) is believed to play an essential role in plaque 
deposition, evidenced by the strong association between elevated serum LDL 
cholesterol and disease (173), and because LDL is the major lipoprotein that 
accumulates in lesions (174). As lesions progress, extracellular lipid accumulation 
predominates and therefore it has been proposed that the ability of macrophages 
and other cells to scavenge LDL is eventually overwhelmed, leading to 
accelerated lipid deposition and formation of the lipid-rich necrotic core (175). 
Therefore, understanding the mechanisms that control macrophage metabolism 
of LDL may be crucial to developing strategies to block atherosclerotic lesion 
progression. 
  LDL is known to be vulnerable to oxidation and it is well established that 
atherosclerotic lesions contain oxidized LDL and lipids (174). Oxidized LDL 
(oxLDL) binds with high affinity to macrophage scavenger receptors thereby 
promoting efficient uptake of oxLDL by these cells (77, 176). Therefore, it is 
widely believed that oxidation of LDL is necessary for the generation of lipid-
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loaded foam cells, a theory that is supported by the identification of oxLDL in 
atherosclerotic lesions (68) and the protective effect of antioxidants in animal 
models of atherosclerosis (177). However, conflicting studies on the role of 
scavenger receptors in murine atherosclerosis (7), as well as disappointing results 
with antioxidants in human clinical trials have generated much controversy about 
the role of oxidized LDL in the disease (177). Numerous alternative theories 
have been proposed, including the popular “response-to-retention hypothesis” in 
which the interaction of lesion LDL with extracellular matrix is a key event in 
lipid deposition (31). 
  More recently, native LDL has been shown to be capable of inducing 
foam cell formation in cultured macrophages (108). Native LDL uptake is much 
less rapid than uptake of oxidized or modified LDL, but at high LDL 
concentrations, nonsaturable mechanisms may contribute significantly to LDL 
uptake. This is especially relevant in the context of hyperlipidemia in which 
LDL-cholesterol concentrations in the serum and in lesions may be higher than 
200 mg/dL (178), several orders of magnitude greater than typical dissociation 
constants of scavenger receptors and other high affinity receptors. Two 
mechanisms have been shown to be involved in cholesterol accumulation in 
cultured macrophages treated with native LDL: fluid-phase pinocytosis of LDL 
particles (108) and, as we have described in Chapter 3, selective cholesteryl ester 
(CE) uptake (179). Studies using pharmacologic inhibition of pinocytosis have 
confirmed that this pathway is required for native LDL-induced loading (108), 
while the net contribution of the selective CE uptake pathway is less certain as 
specific inhibitors are not known. 
  However, the ability of native LDL to induce foam cell formation 
remains controversial, in part because of the suggestion that some degree of 
oxidation or aggregation may occur in the LDL preparation or during incubation 
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with cells and might be responsible for the observed lipid loading (105, 180, 
181). The previous studies using native LDL did not fully address this concern 
because they did not confirm that native LDL was unmodified during treatment, 
and because native LDL was not directly compared to oxidized LDL in the same 
experiments. In the current study, we show that progressive oxidation of LDL 
results in a surprising, complex sequence of changes due to opposite and non-
synchronous effects on LDL particle uptake and selective CE uptake. 
 
 
ADDITIONAL MATERIALS AND METHODS 
 
Reagents 
  Iodide-125 radionuclide (125I) and cholesteryl-1,2-3H(N)]hexadecyl ether 
([3H]CEt) were obtained from Perkin Elmer. 1, 2, 3H(N)cholesteryl linoleate 
([3H]CL) and 1, 2, 3H(N)cholesteryl palmitate ([3H]CP) were synthesized from 
[3H]FC by reaction with excess linoleic anhydride or palmitic anhydride, 
respectively, in toluene followed by purification by thin-layer chromatography 
(TLC)(See Materials and Methods in Chapter 2). [3H]FC Cholesteryl 1, 2, 6, 7 
H(N) oleate ([3H]CO) was purchased from American Radiolabeled Chemicals. 
Radiochemical purity of [3H]lipids was >95% as determined by TLC immediately 
before use in experiments. 
 
Lipoprotein oxidation 
  LDL was oxidized with 20 µM CuSO4 at 37˚C for 0.5-24 hr as described 
(182) except that chloramphenicol and Chelex-100 resin were not included in the 
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pre-oxidation dialysis buffer. Briefly, LDL was dialyzed twice against >2000 
volumes of PBS to remove EDTA. The LDL was diluted with PBS to a 
concentration of 1 mg/mL. CuSO4 was added to a final concentration of 20 µM, 
and the solution was alquoted into 6-well tissue culture plates at 1 mL/well. The 
plate was then incubated in a standard humidified tissue culture incubator (37˚C 
with 5% CO2), during which the oxidation progress was monitored occasionally 
by observing the initial loss of LDL color followed by the later appearance of 
milkiness. After the indicated time period, oxidation was terminated by the 
addition of EDTA (final concentration, 10 mM). Oxidized LDL was dialyzed 
twice against >2000 volumes of 0.9% saline (w/v) with 0.3 mM EDTA to 
remove copper and excess EDTA. oxLDL was analyzed by agarose gel 
electrophoresis (AGE, 1% gel) to determine relative electrophoretic mobility 
(REM) and LDL intactness. LDL aggregation was defined as the percent of total 
125I-LDL in each agarose gel lane that remained trapped within the well. SDS-
PAGE was used to analyze apoB intactness, quantified as the percent of 125I in 
each lane of the developed gel present as intact apoB. oxLDL lipids were 
analyzed by TLC with 3H quantification to determine [3H]CL, [3H]CO and 
[3H]CP content as well as [3H]CL hydroperoxide ([3H]CLOOH) based on the 
positions of the corresponding authentic standards. oxLDL was used for 
experiments within 1 week of preparation, although it was found to be stable to 
these measures of LDL oxidation (AGE, SDS-PAGE and TLC) for at least 2 
weeks. 
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RESULTS 
Comparison of  CE uptake from LDL and oxLDL 
  We previously demonstrated that selective CE uptake is a major pathway 
of cholesterol delivery to macrophages from native LDL (179). However, the 
effect of LDL oxidation on this selective CE uptake pathway is not known. In 
the current investigation, [3H]cholesteryl linoleate- and 125I-dual labeled LDL 
([3H]CL/125I-LDL) was oxidized by treatment with Cu++ at 37˚C for up to 24 hr 
and used for experiments with bone marrow-derived macrophages (BMMs). 
[3H]CL was used because CL is the most common CE in human LDL and is one 
of the major LDL components that is oxidized during LDL oxidation (182). 
[3H]CL was incorporated into the LDL preparation before oxidation so that the 
tracer would be subjected to the same oxidative conditions as the unlabeled CE 
and would therefore trace CL and its oxidation products in the subsequent 
uptake experiments. The degree of oxidation in each LDL preparation was 
determined by quantifying established modifications that occur during LDL 
oxidation (182): increased relative electrophoretic mobility (REM) and LDL 
aggregation (Fig. 4.1A), apolipoprotein B (apoB) fragmentation (Fig. 4.1B) and 
LDL CE oxidation (Fig. 4.1C), as described in Additional Materials and Methods 
in this chapter. 
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Figure 4.1. Characterization of progressive oxidative changes during Cu++-
mediated LDL oxidation. [3H]CL/125I-LDL was oxidized by treatment with 
Cu++ for the indicated time period, and relative electrophoretic mobility was 
determined by agarose gel electrophoresis (A, bands are Sudan Black-stained 
LDL), oxidative fragmentation of apolipoprotein B by SDS-PAGE analysis (B, 
bands are Coomassie-stained apoB, also confirmed by atoradiography), and CE 
oxidation by TLC (C, bands are ferric chloride-stained lipid, s = authentic 
standards) as described in Materials and Methods. Samples were analyzed in 
duplicate (shown in A and B; a second TLC plate was used for the duplicates, 
not shown) and are representative of 2 independent experiments. 
  As expected, LDL oxidation greatly increased subsequent LDL uptake in 
BMMs (Fig. 4.2A, white circles). Several hours of oxidation were required before 
uptake increased, and maximum uptake was observed with 6 hr of oxidation. 
Oxidized LDL exhibited saturable uptake with respect to LDL concentration 
(Fig. 4.3A), consistent with the known involvement of the high-affinity 
scavenger receptors SRA and CD36 (77). Total CE uptake did not follow the 
same pattern (Fig. 4.2A, black circles). Instead, total CE uptake was greatest with 
native LDL (not oxidized, 0 hr) and was progressively decreased with LDLs that 
had been oxidized for 0.5-2 hr. Total CE uptake was increased with LDLs 
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oxidized for 3-6 hr, coincident with the increase in 125I-LDL uptake, followed by 
a gradual decrease in the uptake of LDLs oxidized 6-24 hr. The difference 
between [3H]CE uptake and 125I-LDL uptake is defined as selective CE uptake, 
and indicates CE acquired by cells independent of LDL particle uptake. Selective 
CE uptake was progressively impaired by LDL oxidation and was reduced by 
>90% in 24hr-oxLDL (Fig. 4.2A, gray circles). As we previously reported (179) 
and in contrast to 125I-oxLDL uptake, selective CE uptake was non-saturable 
with respect to LDL concentration (Fig. 4.3B). 
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Figure 4.2. Comparison of LDL uptake and selective CE uptake to indices 
of LDL oxidation. Oxidized [3H]CL/125I-LDL (with the indicated oxidation 
period, using the samples shown in Figure 1) was incubated with BMMs (500 
µg/mL) in medium B for 4 hr. After the treatment period, LDL uptake (white 
circles, A), total CE uptake (black circles, A) and selective CE uptake (gray 
circles, A-D) were determined as described in Materials and Methods. REM 
(black squares) and LDL aggregation (white squares) of the oxLDL preparations 
were determined by AGE (B), intact apoB (white squares) by SDS-PAGE (C) 
and [3H]CL (black squares) and [3H]CLOOH (white squares) by TLC (D). 
Values for LDL uptake, total CE uptake and selective CE uptake are the mean 
+/- S.E.M. of pooled data from 2 independent experiments (n=3 in each), and 
other values are the mean +/- S.E.M. of duplicate determinations. 
Figure 4.3. Concentration dependence of nLDL and oxLDL metabolism. 
[3H]CL/125I-LDL (nLDL, white circles) or [3H]CL/125I-LDL that was oxidized 
by treatment with Cu++ for 2hr (2hr-oxLDL, gray circles) or 24 hr (24hr-oxLDL, 
black circles) was incubated with macrophages at the indicated concentration in 
medium B for 4 hr. After the treatment period, LDL uptake (A), and selective 
CE uptake (B) were determined as described in Materials and Methods. Values 
are the mean +/- S.E.M. (n=3) and are representative of 2 independent 
experiments. 
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Correlation between impairment of  selective CE uptake and LDL 
oxidative changes 
  This is the first report of reduced selective CE uptake from oxidized 
LDL, and the mechanism by which this pathway is impaired is not known. We 
considered the possibility that substantial changes that can occur in LDL 
structure and composition may be responsible. Therefore, we compared the 
timing of reduced selective CE uptake to the measures of LDL oxidation shown 
in Fig. 4.1.   Changes in REM and LDL aggregation did not appear to be 
correlated to changes in selective CE uptake as substantial reductions occurred in 
the latter during the first 2 hours of oxidation, whereas REM and LDL 
aggregation exhibited little or no change, respectively (Fig. 4.1B). As previously 
described, modification of apoB is one of the earliest changes during LDL 
oxidation and is characterized by a rapid loss of intact apoB (MW ~517 kDa), 
followed by the appearance of apoB fragments (183). Interestingly, the loss of 
intact apoB correlated closely with the reduction in selective CE uptake, 
indicating that this modification may be involved in the impairment of selective 
uptake. 
  Finally, selective CE uptake was compared to oxidation of LDL CE, 
measured by thin-layer chromatography (Fig. 4.2D). CE oxidation may be 
especially relevant to CE uptake as CE oxidation products may have altered 
selective uptake capacity. In addition, one group of oxidized CE products, CE 
hydroperoxide, has been shown to exert specific biological effects in 
macrophages, including induction of LDL pinocytosis (184). However, CE 
oxidation (measured as loss of intact [3H]CL) and the generation of cholesteryl 
linoleate hydroperoxide ([3H]CL-OOH) occurred only after a lag phase of several 
hours, during which selective uptake was markedly reduced (Fig. 4.2D). 
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Therefore, the impairment of selective CE uptake did not require CE oxidation 
and was not directly associated with CE-hydroperoxide content. 
  The effect of CE oxidation on selective CE uptake was also studied by 
incorporating three different radiolabeled CEs into parallel LDL preparations: 
[3H]cholesteryl linoleate, [3H]cholesteryl oleate or [3H]cholesteryl palmitate 
([3H]CL, [3H]CO or [3H]CP, respectively), tritiated analogs of the three most 
abundant CEs in human LDL. During LDL oxidation, these three CEs were 
oxidized at different rates, with [3H]CL oxidized most rapidly and [3H]CP least 
rapidly (Fig. 4.4A), consistent with previous reports (182). However, selective CE 
uptake of each of these ligands was impaired, regardless of the extent of CE 
tracer oxidation (Fig. 4.4B). In addition, when a [3H]CEt tracer was incorporated 
after LDL oxidation, to ensure that none of the tracer was oxidized, selective CE 
uptake was reduced similarly (Fig. 4.5). In the latter experiment, lack of [3H]CEt 
tracer oxidation was confirmed by TLC analysis of the media after the 
experiment. Together, these results provide strong evidence that reduced 
selective CE uptake is not the result of oxidative modification of CE. 
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Figure 4.4. Comparison of oxidation and uptake of LDL CP, CO and CL. 
[3H]CP/125I-LDL (CP-LDL, black circles), [3H]CO/125I-LDL (CO-LDL, gray 
circles) or [3H]CL/125I-LDL (CL-LDL, white circles) were oxidized by treatment 
with Cu++ for the indicated time period, then incubated with BMMs (500 
µg/mL) for 4 hr in medium B. [3H]CP, [3H]CO or [3H]CL remaining unoxidized 
in the LDL preparations was determined by TLC (A) and LDL uptake and 
selective CE uptake in BMMs determined as described in Materials and Methods 
(B). Values in B are the mean +/- S.E.M. (n=3). 
 
Figure 4.5. Effect of LDL oxidation on selective uptake of unoxidized CE. 
[3H]CEt was incorporation into 125I-LDL (nLDL) or LDL that was previously 
oxidized by treatment with Cu++ for 1hr (1hr-ox) or 4 hr (4hr-ox). [3H]CEt was 
incorporated after the oxidation period to avoid oxidation of the [3H]CEt tracer 
in this experiment, and 500 µg/mL [3H]CEt/125I-LDL or oxidized [3H]CEt/125I-
LDL was then incubated with macrophages in medium B for 4 hr. Lack of 
[3H]CEt oxidation was confirmed by TLC both before and after the experiment. 
After the treatment period, selective CE uptake and LDL uptake were 
determined as described in Materials and Methods. Values are the mean +/- 
S.E.M. (n=3) and are representative of 2 independent experiments. **, p<0.01 
compared to the corresponding nLDL value; **, p<0.001. 
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Inhibition of  selective CE uptake from LDL by co- or pre-treatment with 
oxLDL 
 Reduced selective CE uptake from oxidized LDL may be due to 1) 
reduced capacity of the particles for selective CE uptake and/or 2) an inhibitory 
effect of oxLDL on the cellular selective CE uptake pathway. These possibilities 
were not distinguished in the previous experiments using [3H]CE/125I-oxLDL. 
Therefore, selective CE uptake from [3H]CL/125I-LDL was investigated in cells 
which were co-incubated (Fig. 4.6A-B) or pre-incubated (Fig. 4.6C) with LDL or 
oxLDL. In both experiments, 500 µg/mL oxLDL was used so that results could 
be compared to previous experiments carried out at this concentration. 
Interestingly, co-incubation with oxidized LDL significantly impaired selective 
uptake from [3H]CL/125I-LDL (Fig. 4.6A) to a degree comparable to previous 
experiments (Figs. 4.2-4.5). The [[3H]CL/125I-LDL may have been oxidized by 
exposure to oxLDL in the culture media; however, the extent of such cross-
oxidation was minimal since loss of intact apoB (the most sensitive measure of 
oxidation used in this investigation) was less than 20% in the culture media after 
the experiment (Fig. 4.6B). There was no evidence of increased REM or [3H]CL 
oxidation by AGE and TLC, respectively (data not shown). These result 
supports the hypothesis that reduced selective CE uptake with oxidized LDL is 
at least partly due to possibility 2) above. 
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Figure 4.6. Inhibition of selective CE uptake from native LDL by oxLDL 
cotreatment or pretreatment. A, B. BMMs were treated for 4 hr in medium B 
with 500 µg/mL of [3H]CL/125I-LDL with or without the indicated addition of 
500 µg/mL nLDL or oxLDL, and selective CE uptake and LDL uptake (A) or 
selective CE uptake and intact apoB (B) were determined as described in 
Materials and Methods. C. BMMs were pretreated for 4 hr in medium B with or 
without the indicated addition of 500 µg/mL nLDL or oxLDL, then washed 
thoroughly and treated with 500 µg/mL [3H]CL/125I-LDL in medium B for 1 hr. 
Selective CE uptake and LDL uptake were determined as described in Materials 
and Methods. Values are the mean +/- S.E.M. (n=3). *, p<0.05 compared to 
control (-); **, p<001; ***, p<0.001. 
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 However, interpretation of the co-incubation experiment is complicated 
by several factors. First, [3H]CL could possibly be transferred from [3H]CL/125I-
LDL to the unlabeled oxLDL during the experiment. This possibility was not 
directly tested but seems unlikely in the absence of cholesteryl ester transfer 
protein (CETP, a serum protein that is removed during the purified LDL 
preparation)(185). Second, the combined presence of high concentration 
oxidized LDL and native LDL could induce cell toxicity, although the period of 
treatment was short (4 h) and no signs of cell stress (cell detachment, cell 
rounding, etc.) were observed in the experiment. Nonetheless, a second 
experiment was carried out to confirm that the inhibition of selective CE uptake 
by oxidized LDL could be observed even after the oxLDL is removed from the 
treatment medium (Fig. 4.6C). In this experiment, cells were pre-treated for 4 h 
with or without LDL or oxLDL, then washed to remove the pre-treatment 
ligands and medium and treated for 30 minutes with [3H]CL/125I-LDL. The 
treatment period was kept short to examine selective uptake immediately after 
the removal of oxLDL. In this experiment, only a more extensively oxidized 
LDL (8r-oxLDL) reduced selective CE uptake, and this treatment also reduced 
LDL particle uptake to nearly the same degree (Fig. 4.6C). Therefore, the results 
of the co-treatment and pre-treatment experiments are not conclusive but 
suggest that reduced selective uptake may be due in part to effects on the 
macrophages, at least with the more extensively oxidized LDL. 
 
Cholesterol accumulation and lipid droplet deposition in BMMs treated 
with LDL or oxLDL. 
   The cholesterol content of cells is influenced by cholesterol efflux 
during treatments and therefore does not always relate quantitatively to measured 
CE uptake (179). Therefore, net cholesterol accumulation was examined by 
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measuring cellular cholesterol content after a 24 hr loading period with native or 
oxLDL (Fig. 4.7). BMMs treated without lipoproteins (0 µg/mL group) 
contained ~117 nmol free cholesterol (FC) per mg cell protein and did not 
contain a significant amount of CE (calculated as the difference between total 
cholesterol and FC content). nLDL treatment resulted in significant, 
concentration-dependent cholesterol accumulation, with FC and CE increasing 
as much as 1.7 and 4.7-fold, respectively. In contrast, 1.5hr-oxLDL induced only 
minimal changes in FC (<30%) and did not significantly alter CE content. As 
expected, 8 hr-oxLDL or 24hr-oxLDL treatment resulted in pronounced 
accumulation of both FC and CE, which increased as much as 5.8- and 26.7-
fold, respectively. Together, these results indicated that native LDL and 
extensively oxidized LDL, but not minimally oxidized LDL, induced net 
cholesterol accumulation. 
     
Figure 4.7. FC and CE content in cells treated with nLDL or oxLDL. 
BMMs were treated for 24 hr with the indicated addition in medium B. Cellular 
FC and CE content was determined as described in Materials and Methods. 
Values are the mean +/- S.E.M. (n=3) and are representative of 2 independent 
experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to control (0 
µg/mL). 
 
 
94 
  LDL-induced foam cell generation was assessed by Oil Red-O staining of 
neutral lipid droplets (Fig. 4.8). Cells treated for 24 h without lipoproteins did 
not contain Oil Red-O-positive lipid droplets (data not shown). As expected, 
treatment with 8hr-oxLDL or 24hr-oxLDL induced foam cell generation at 
either 100 µg/mL or 500 µg/mL. In contrast, native LDL resulted in visible 
neutral lipid droplet deposition only at the higher concentration (500 µg/mL), 
consistent with the quantification of CE in cells (Fig. 4.7) and with our previous 
observation of lipid loading by native LDL through a low-affinity and 
nonsaturable process (179), described in Chapter 3. Interestingly, 1.5h-oxLDL 
(500 µg/mL) induced much less lipid deposition compared to native LDL, in 
line with difference in CE accumulation induced by these ligands (Fig. 4.7). The 
morphology of the lipid-loaded cells was examined at higher magnification and 
revealed distinct differences in the type and distribution of the oil red O-stained 
droplets (Fig. 4.8B). The lipid droplets formed during treatment with native LDL 
were less numerous but much larger than those formed during treatment with 
oxidized LDL and appeared localized towards the cell periphery, in contrast the 
droplets induced by oxLDL, which were widely spread throughout the 
cytoplasm.  Therefore, cells loaded with native LDL were easily distinguished 
from those treated with oxLDL. 
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Figure 4.8. Oil Red O-staining of neutral lipid droplets in BMMs treated 
with nLDL or oxLDL. BMMs were treated for 24 hr with the indicated 
addition in medium B, stained with Oil Red-O and visualized by light 
microscopy at low magnification (A) or high magnification (B) as described in 
Materials and Methods. Results are representative of 2 independent experiments. 
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Macrophage conditioning of  LDL and effect on CE uptake and foam 
cell generation in fresh macrophages. 
 While Cu++-oxidized LDL is a useful experimental model, LDL oxidation 
that occurs in vivo is unlikely to be caused by free transition metals. However, 
macrophages and other cells have been shown to be capable to enhancing LDL 
oxidation without a requirement for transition metals (180). Therefore, the 
possibility was considered that during treatment of macrophages with native 
LDL in the current study, some oxidation might have occurred in the culture 
media. Interestingly, while there was evidence by SDS-PAGE that apoB 
modification occurred over the course of 1-5 days (Fig. 4.9A), there was no 
evidence of increased REM or CE oxidation compared to native LDL (data not 
shown). This likely indicates a minimal extent of LDL oxidation during these 
treatments, comparable to LDL oxidized by Cu++ for 2 hr or less. However, 
LDL that had been exposed to macrophages in culture for 1-2 days, then 
collected and transferred to fresh macrophages, induced significantly less lipid 
droplet deposition compared to native LDL (Fig. 4.9B). In addition, selective CE 
uptake from macrophage-conditioned LDL was markedly reduced (Fig. 4.9C). 
These results are consistent with the results described above for minimally Cu++-
oxidized LDL and suggest that LDL oxidation resulting from physiologically 
relevant conditions may reduce selective CE uptake and the resulting foam cell 
generation. 
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Figure 4.9. LDL oxidation during incubation with macrophages and 
effect on selective CE uptake and foam cell formation in fresh 
macrophages. [3H]CE/125I-LDL (A-C) or LDL (D) was incubated with BMMs 
for the indicated time period, and CE and FC content (A) were determined as 
described in Materials and Methods. apoB was analyzed by SDS-PAGE with 
autoradiography (B).  The conditioned LDLs were dialyzed overnight against 50 
volumes of RPMI, then transferred to fresh macrophages and incubated for 4 h 
(C) or 24 h (D). Selective CE uptake and LDL uptake were determined as 
described in Materials and Methods (C) and cells were stained with Oil Red-O and 
visualized by light microscopy. Results are representative of 2 independent 
experiments. 
 
 
DISCUSSION 
  Many studies have shown that native LDL induces little cholesterol 
accumulation in cultured macrophages compared to acetylated LDL (acLDL) 
(176) or oxidized LDL (oxLDL) (186). However, these investigations were 
carried out at low LDL concentrations. The current investigation clearly 
demonstrates that native LDL induces foam cell generation at high 
 
 
98 
concentrations (similar to the results presented in Chapter 3), and that lipid 
accumulation induced by native LDL is distinct from that induced by oxLDL as 
both the pathway of uptake and the morphology and distribution of lipid 
droplets are different. Native LDL cholesterol was acquired largely via low-
affinity or nonsaturable selective CE uptake, leading to the formation of large 
lipid droplets that are typically arranged near the cell periphery. In contrast, 
oxLDL was taken up with high-affinity as whole particles and resulted in profuse 
deposition of small lipid droplets, similar to previous reports (187). While the 
cholesterol accumulation observed in native-LDL treated cells was less than 
oxLDL-treated cells, native LDL was shown previously to be capable of 
inducing extensive lipid deposition at higher concentrations due to the 
nonsaturable mode of uptake (179). These findings should help to resolve the 
controversy surrounding native LDL-induced foam cell formation as they 
provide the first strong evidence that this phenomenon does not involve LDL 
oxidation. 
  The major novel observation of the current chapter is that LDL 
oxidation resulted in progressive impairment of selective CE uptake. The reason 
for this impairment is not known and may involve a combination of multiple 
factors. While the inhibition of selective uptake was greatest with extensive LDL 
oxidation, a significant reduction occurred with very minimal LDL oxidation. At 
this stage of oxidation, there was no evidence of altered macrophage LDL 
particle uptake or substantial changes in LDL electrical charge, aggregation or 
CE oxidation, similar to the commonly used “minimally modified LDL” 
produced by cells expressing 15-lipoxygenase (188). This suggests that reduced 
selective uptake does not require the modifications that promote scavenger 
receptor-mediated uptake in more extensively oxidized LDL. Instead, the 
impairment of selective CE uptake correlated closely with apoB fragmentation 
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that occurred very early in LDL oxidation. Oxidative peptide fragmentation is a 
unique feature of apoB and is not fully understood; however, it is thought to 
involve direct scission of peptide bonds by free radical-containing phospholipid 
oxidation products (189).  Phospholipid and protein forms the shell of 
lipoproteins through which CE must traverse in order to be transferred to cells 
by selective uptake, so it is conceivable that derangement of this surface layer in 
minimally oxidized LDL could impact the rate of selective CE uptake.  
  Alternately, impaired selective CE uptake may be due to an inhibitory 
effect of the oxLDL on the macrophages. The co-treatment and pre-treatment 
experiments in this chapter support this possibility, especially with more 
extensively oxidized LDLs. These treatments inhibited selective CE uptake from 
native LDL by more than 50%. Oxidized LDL, including very mildly oxidized 
LDL, has been shown to have many biological effects in macrophages, including 
induction of actin polymerization, reactive oxygen species production and 
cytokine expression and reduced phagocytic activity (188). Many of these effects 
were shown to be mediated by oxidized CE products. While CL oxidation was 
not required for reduced selective CE uptake in the results presented in this 
chapter, it is possible that the presence of oxidized CEs, some of which are 
generated more rapidly than CL oxidation products (e.g. cholesteryl arachidonate 
hydroperoxide) (182), could have biological activity that inhibit macrophage 
selective CE uptake. Other possible active components of LDL include oxidized 
phospholipids (oxPLs) and the oxidized fatty acid products released from oxPL 
hydrolysis (188). It will be useful to isolate various lipid and non-lipid fractions 
of oxLDL to determine if any purified component can inhibit selective CE 
uptake. 
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  Importantly, minimal oxidation of LDL largely prevented foam cell 
formation. This is the first report of an oxidized LDL inducing less macrophage 
lipid accumulation than native LDL, a finding that was apparent only at a high 
LDL concentration and was likely missed in previous investigations due to the 
lower LDL concentrations used. This observation has several important 
implications. First, this provides further evidence that oxidation is not involved 
in native LDL-induced lipid loading, since mild oxidation of LDL that may occur 
during LDL isolation and during treatment of cells would be expected to 
decrease the observed loading. Indeed, macrophage conditioning of LDL 
reduced CE uptake and foam cell generation when transferred to fresh 
macrophages (Fig. 4.9). 
  Second, while lipid loading was almost completely eliminated by minimal 
oxidation of LDL, LDL particle uptake including pinocytosis was not decreased, 
indicating that the pinocytic pathway alone is not sufficient for foam cell 
generation. Previous studies established that macrophage LDL pinocytosis is 
required for foam cell formation (108) but did not rule out the possibility that 
another pathway also contributed to cholesterol uptake. In fact, selective CE 
uptake was reduced by minimal LDL oxidation, suggesting that the selective 
uptake pathway is also required for the lipid loading induced by native LDL. This 
hypothesis is supported by the large proportion of cholesterol supplied by the 
selective pathway and by previous studies of the metabolism of CE following 
selective uptake, presented in Chapter 3 (179). 
  Finally, reduced foam cell formation with minimally oxidized LDL 
suggests that LDL oxidation that occurs in atherosclerotic lesions may reduce 
cellular lipid uptake and accumulation under conditions in which the extent of 
oxidation is limited. We propose that this effect is quite relevant to 
atherosclerosis because analysis of oxidized lipids in human lesions suggests that 
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on average, LDL oxidation is mild (<2.5% and <1% of cholesteryl linoleate and 
cholesterol oxidized, respectively) (190). The use of antioxidants and related 
strategies may slow this initial oxidation and thus prolong foam cell generation 
via selective CE uptake from native LDL. This may be one reason why 
antioxidant strategies have not always been effective in the treatment of 
atherosclerosis (177). On the other hand, reduced uptake of mildly oxidized 
LDL into macrophages may lead to extracellular lipid accumulation that may in 
turn promote lipid core formation and plaque progression. Macrophage foam 
cell formation is widely believed to promote lesion progression, but this theory 
has yet to be demonstrated in vivo. The development of new animal models in 
which macrophage uptake of native LDL is altered will be necessary to 
determine the true function of these pathways in atherosclerosis. 
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CHAPTER 5: SUMMARY, IMPACT AND FUTURE DIRECTIONS 
 
Summary of  major findings 
The goal of this dissertation project was to define the basic pathway of 
macrophage selective CE uptake and to quantify its contribution to macrophage 
foam cell formation induced by native LDL or oxidized LDL. Results in Chapter 
3 demonstrated that the majority of cholesterol taken up from native LDL is 
acquired via selective CE uptake, with smaller quantities derived from uptake of 
whole LDL particles. In Chapter 4, LDL oxidation was shown to impair 
macrophage selective CE uptake so that cholesterol uptake from oxidized LDL 
was primarily via whole-particle uptake. Therefore, selective CE uptake is a 
major mode of macrophage cholesterol acquisition from native LDL but not 
oxidized LDL. The selective CE uptake pathway was characterized by CE 
transfer from LDL to cells, followed by rapid CE hydrolysis, likely in lysosomes, 
and efflux of much of the generated FC. Interestingly, LDL-induced CE 
accumulation and lipid droplet formation differed from that induced by either 
acLDL (ACAT-dependent) or oxLDL (much smaller and more numerous lipid 
droplets). The molecular basis of macrophage selective CE uptake, including 
proteins and cellular structures potentially involved in CE transport, is not 
known but this pathway was shown to be independent of actin-mediated 
pinocytosis and the class B scavenger receptors SR-BI and CD36. 
 
Impact 
  The results of this dissertation are unexpected in the context of the 
current field of macrophage lipoprotein metabolism. First, it is generally accepted 
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that native LDL does not induce significant cholesterol accumulation in 
macrophages and that some type of modification, especially LDL oxidation, is 
required before foam cells can be generated. Kruth and colleagues challenged 
this notion in 2002 by showing that human macrophages may be converted to 
foam cells by treatment with high concentration native LDL (105). The work 
presented in this dissertation supports Kruth’s findings by showing a similar 
pattern in murine BMMs. In addition, the current results strengthen the 
“unmodified LDL” hypothesis by showing that oxidation in the LDL 
preparation cannot explain LDL-induced foam cell formation.  Foam cells 
generated with LDL are clearly distinguished from those generated with oxLDL 
(Chapter 4).  
Second, all of the major proposed pathways of macrophage foam cell 
generation to this point involved whole-particle LDL uptake. Scavenger 
receptor-mediated oxLDL uptake, phagocytosis of LDL aggregates and 
pinocytosis of native LDL are just a few examples, but there are many more in 
the literature (191). Virtually all of these studies investigated whole-particle 
lipoprotein uptake and did not measure the uptake of the cholesterol directly. 
The possible contribution of selective CE uptake to macrophage cholesterol 
accumulation was considered and tested in 1979 by Goldstein and Brown in 
their studies of acLDL metabolism (139), but was not revisited in subsequent 
studies. The major contribution of this dissertation project is to establish that 
macrophage selective uptake of LDL CE is one pathway of macrophage 
cholesterol accumulation that occurs independently of lipoprotein particle uptake 
and degradation. 
Selective CE uptake from native LDL may be a major pathway of foam 
cell generation in atherosclerotic lesions; a possibility that is consistent what is 
known about the disease. The LDL concentration in the human arterial intima is 
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1 mg/mL or greater (45), which has been shown in the current investigation to 
be sufficient to induce macrophage foam cell formation in 24 h. Some of the 
intima LDL may be aggregated or bound to extracellular matrix, but much of it 
is present as monomeric LDL that can be isolated intact from lesions, as 
discussed in Chapter 1. The nonsaturable manner of uptake and foam cell 
formation with native LDL may explain why high levels of plasma LDL are 
associated with disease progression (60). Humans and animals with genetic 
mutations resulting in very high LDL levels have greatly accelerated 
atherosclerosis (192-197). 
In contrast, it appears to be unlikely that extensively oxidized LDL that 
promotes foam cells via scavenger receptors exists in large quantities in 
atherosclerotic lesions. There is strong evidence that oxidized LDL is present in 
lesions (68); however, the extent of oxidation is likely to be mild and insufficient 
to induce foam cell formation (190). Hypercholesterolemic mice deficient in 
scavenger receptors have abundant foam cell formation (7), demonstrating that 
these pathways are not required for foam cell formation in vivo. It is more likely 
that mildly or minimally oxidized LDL exhibits other effects that may be 
atherogenic, including the activation of endothelium, monocyte recruitment and 
modulation of macrophage phenotype (188). This dissertation suggests that 
minimally oxidized LDL may also reduce selective CE uptake from LDL, 
potentially decreasing foam cell generation and lesion LDL metabolism. 
 
Future directions 
The work presented in this dissertation has defined the basic properties of 
macrophage selective CE uptake and its contribution to foam cell formation in 
cultured macrophages. However, this pathway remains poorly understood, 
especially with regards to the molecular components that mediate CE transport. 
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Further investigation of the mechanism of macrophage selective CE uptake will 
be necessary in order to generate molecular targets for studies in experimental 
animals and humans. The studies carried out in this dissertation form an 
important background for such an investigation. This section will discuss 
possible experimental approaches for future work. 
The most impressive feature of the macrophage selective CE uptake 
pathway is the large volume of CE transported into the cells. It is clear that this 
pathway has a high capacity for CE, with no apparent saturability at high LDL 
concentrations. The rate of uptake was as high as ~100 nmol CE/mg cell 
protein/h at 1000 µg/mL LDL (Chapter 3). These rates are higher than any 
reported for CE uptake in any cell type.  In comparison, in mouse peritoneal 
macrophages (MPMs) that express high levels of SR-A, CE uptake from acLDL 
was reported to be about ~20 nmol CE/mg cell protein/h (139); adrenal cells 
with high SR-BI expression take up HDL CE at ~5  nmol CE/mg cell protein/h 
(198). In addition, [3H]CEt uptake was as large as [3H]CE uptake, indicating that 
CE is taken up intact. Following uptake, this large amount of [3H]CE is 
hydrolyzed within ~30 minutes. Therefore, a very efficient mechanism of CE 
transport is envisaged. 
Based on the rapid initial rate of [3H]CEt uptake compared to 125I-LDL 
uptake (Chapter 3), the first step of macrophage selective CE uptake appears to 
be transfer of CE from LDL to cells (rather than LDL particle uptake and 
recycling, for example). The nature and location of the site into which CE might 
be transferred is not known. The plasma membrane and specifically caveoli, 
specialized plasma membrane structures rich in FC and sphingomyelin, have 
been shown to be initial CE acceptors in SR-BI-expressing cells (119). Caveoli 
have been isolated by a number of techniques, including a density gradient 
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fractionation technique that avoids the use of detergents (199). These techniques 
could be used to localize LDL-derived [3H]CEt or [3H]CE in cell fractions. 
It is possible that the plasma membrane is the CE acceptor in 
macrophages as well; however, the normal capacity of the plasma membrane for 
CE is only about 2% CE as a molar ratio to phospholipid (200), and based on 
the phospholipid content of macrophages (201), this would amount to ~2 nmol 
CE/mg cell protein. The plasma membrane would need to turn over 50 times 
every hour to be responsible for the rates of CE uptake measured in this 
investigation. Macrophages have rapid internalization of plasma membrane (the 
entire surface every ~30 minutes) (202) but not sufficient to explain the rates 
described here.  The turnover of [3H]CE in pulse-chase experiments in this 
dissertation was similar (t1/2 = 30 min, Chapter 3). It is therefore likely that the 
cellular acceptor site has a much higher capacity for CE than a pure 
phospholipid bilayer. 
In fact, intact [3H]CE accumulated in cells at ~30-100 nmol [3H]CE/mg 
cell protein, representing a large enough pool to account for the rates of CE 
uptake (Chapter 3). Even when hydrolysis was blocked by reduced temperature 
treatment or with chloroquine, macrophages accumulated 60 nmol [3H]CE/mg 
cell protein. LDL-derived CE accumulation is also independent of ACAT, unlike 
acLDL CE metabolism, as lipid droplets and LDL-derived [3H]CE accumulated 
in the presence of an ACAT inhibitor. These results suggest the possibility that 
CE is directly deposited into lipid droplets during treatment with LDL (i.e. 
without being hydrolyzed and re-esterified). 
However, additional studies are needed to test this hypothesis. First, more 
specific inhibitors of CE hydrolysis would be useful, as chloroquine and reduced 
temperature treatments may have broad effects on cells. Lalistat is a more 
specific inhibitor of lysosomal acid lipase that could be used (203). Second, the 
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rate of re-esterification needs to be measured directly. This could be done by 
measuring conversion of LDL-derived [3H]CL into [3H]CO (oleate is the 
preffered substrate of ACAT, leading to CO production) (139). Third, the 
localization of lipid droplets in cells treated with LDL needs to be defined; 
specifically, cytoplasmic and lysosomal localization could be tested by staining 
cells with perilipin and Lysotracker, respectively. 
 Finally, while the CE in lipoproteins and lipid droplets is surrounded by a 
layer of phospholid, proteins are also associated with the CE and make direct 
contact with CE (204, 205). Proteins that contact CE may be involved in the 
mechanism of selective CE uptake and are therefore major candidates for 
targeting this pathway. The direct interaction of these proteins also suggests the 
possibility that they could be specifically identified using a crosslinking technique. 
Two photoactive crosslinking cholesterol analogs, 6, 6, azocholesterol and 7, 7-
azocholesterol, and their 3H-labeled versions are commercially available from 
American Radiolabeled Chemicals. These have been used to identify cellular 
proteins that interact with FC (206). The corresponding esters have also been 
made (125) but have not been utilized to identify CE-interacting proteins. 
Incorporation of [3H]azo-cholesteryl ester into LDL and treatment of 
macrophages, followed by analysis of crosslinked proteins by 3H autoradiography 
of SDS-PAGE gels and mass spectrometry, could be a very informative research 
direction. 
Another interesting clue about the selective CE uptake pathway is the 
impaired uptake from minimally oxidized LDL and the apparent inhibition of 
this pathway by the presence of oxLDL. As discussed in Chapter 4, the 
mechanism for this inhibition is not known, but could involve the production of 
bioactive lipids, such as oxidized phospholipids or CEs. CL hydroperoxide has 
been previously shown to covalently adduct to proteins (207), thereby acting 
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similar to a crosslinking reagent. The capacity of CE hydroperoxide and other 
CE oxidation products to be taken up by selective uptake is not known, but 
these could potentially be used as described for the photoactive cholesterol 
analogs to identify proteins involved in CE transport. 
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APPENDICES 
ABBREVIATIONS 
[3H]CE   -   [3H]cholesteryl ester 
[3H]CEt   -   [3H]cholesteryl ether 
[3H]CL    -   [3H]cholesteryl linoleate 
[3H]CL- 
OOH     -   [3H]cholesteryl linoleate hydroperoxide 
[3H]CO   -   [3H]cholesteryl oleate 
[3H]CP    -   [3H]cholesteryl palmitate 
[3H]FC    -   [3H]cholesterol 
AGE     -   agarose gel electrophoresis 
ACAT    -   Acetyl-Coenzyme A acetyltransferase 
ACVD    -   atherosclerotic cardiovascular disease 
acLDL    -   acetylated LDL 
agLDL    -   aggregated LDL 
aggLDL   -   aggregated LDL 
apoB     -   apolipoprotein B 
BCA     -   bicinchronic acid assay 
BMM     -   bone marrow-derived macrophage 
BSA     -   bovine serum albumin 
CD36     -   cluster of differentiation 36 
cDNA    -   complementary deoxyribonucleic acid 
CE     -   cholesteryl ester 
CHO     -   Chinese hamster ovary 
CVD     -   cardiovascular disease 
cyto D    -   cytochalasin D 
DMSO   -   dimethylsulfoxide 
EDTA    -   ethylenediaminetetraacetic acid 
FC     -   free cholesterol (cholesterol) 
FH     -   familial hypercholesterolemia 
GM-CSF  -   granulocyte-macrophage colony stimulating factor 
HDL     -   high density lipoprotein 
HEPES   -   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HMG- 
CoA  
Reduc- 
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Tase     -   3-hydroxy-3-methyl-glutaryl-CoA reductase 
LAL     -   lysosomal acid lipase 
lat B     -   latrunculin B 
LDL     -   low density lipoprotein 
LDL-R   -   low density lipoprotein receptor 
LRP     -   low density lipoprotein receptor-related protein 
LXR     -   liver X receptor 
M-CSF    -   macrophage colony stimulating factor 
MPM     -   murine peritoneal macrophage 
nLDL     -   native low density lipoprotein (same as LDL) 
ORO     -   Oil Red-O 
oxLDL   -   oxidized low density lipoprotein 
REM     -   relative electrophoretic mobility 
PBS     -   phosphate-buffered saline 
PUFA     -   polyunsaturated fatty acid 
SDS- 
PAGE    -   sodium dodecylsulfate-polyacrylamide gel electrophoresis 
S.E.M.    -   standard error of the mean 
SR-A     -   scavenger receptor A 
SR-B     -   scavenger receptor B 
SR-BI     -   scavenger receptor B, type I 
TLC     -   thin-layer chromatography 
UBP     -   diethylumbelliferyl phosphate 
VLDL    -   very low density lipoprotein 
WT     -   wild type 
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